  
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  ***CONFIDENTIAL*** 
The Insulin-Only Bionic Pancreas Pi[INVESTIGATOR_243897]: 
Testing the iLet in Adults and Children with Type 1  Diabetes 
Version 10.0 
25 April 2021 
 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  PAGE 2 OF 97 Clinical Study Leadership 
Steven Russell, MD (Director) 
Courtney Balliro, BS, RN, CDE (Assistant Director) 
[LOCATION_005] General Hospi[INVESTIGATOR_263199], MA 
Engineering and Technology Center 
Edward Damiano, PhD (Director and Project Principal  Investigator) 
Firas El-Khatib, PhD (Associate Director) 
[LOCATION_011] University, Biomedical Engineering Departmen t 
[LOCATION_011], MA 
National Coordinating Center 
Roy W. Beck, M.D., Ph.D. (Director) 
Katrina J. Ruedy, MSPH (Co-Director) 
Jaeb Center for Health Research 
Tampa, FL 
 
 
 
 
 
 
 
 
  
 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  PAGE 3 OF 97 SITE PRINCIPAL INVESTIGATOR [INVESTIGATOR_113411]: The Insulin-Only Bionic Pancreas Pi [INVESTIGATOR_243897]: Testing the iLet in Adults and 
Children with Type 1 Diabetes 
Protocol Version/Date: Version 10.0/[ADDRESS_319991] read the protocol specified above.  In my fo rmal capacity as a Site Principal 
Investigator, my duties include ensuring the safety  of the study participants enrolled under 
my supervision and providing the Jaeb Center for He alth Research, which serves as the 
Coordinating Center for the protocol, with complete  and timely information, as outlined in 
the protocol.  It is understood that all informatio n pertaining to the study will be held strictly 
confidential and that this confidentiality requirem ent applies to all study staff at this site. 
This trial will be carried out in accordance with I CH E6 Good Clinical Practice (GCP) and as 
required by [CONTACT_716] (use applicable regulatio ns depending on study location and 
sponsor requirements; examples follow): United Stat es (US) Code of Federal Regulations 
(CFR) applicable to clinical studies (45 CFR Part 4 6, 21 CFR Part 50, 21 CFR Part 56, 21 
CFR Part 312, and/or 21 CFR Part 812). 
As the Principal Investigator, I will assure that n o deviation from, or changes to the protocol 
will take place without prior agreement from the sp onsor and documented approval from the 
Institutional Review Board (IRB), or other approved  Ethics Committee, except where 
necessary to eliminate an immediate hazard(s) to th e trial participants. 
All key personnel (all individuals responsible for the design and conduct of this trial) have 
completed Human Participants Protection Training an d Good Clinical Practice Training.  
Further, I agree to ensure that all staff members i nvolved in the conduct of this study are 
informed about their obligations in meeting the abo ve commitments. 
Investigator’s Signature __________________________ _____ Date: _____ / _____ / _____ 
 dd mmm yyyy 
Investigator’s Name: ______________________________ ______  
Site Name: ________________________________________ ____ 
  
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  PAGE 4 OF 97 TABLE OF CONTENTS  
CHAPTER 1:  INTRODUCTION  .................................................. ................................................... ................ 20  
1.1 Background and Rationale ...................... ................................................... ........................................ 20  
1.2 Bihormonal BP System .......................... ................................................... ........................................ 21  
1.3 Insulin-Only BP System ........................ ................................................... ......................................... 23  
1.3.1 iPhone-Based BP System ...................... ................................................... ................................... 23  
1.3.2 Fully Integrated iLet ®  BP System (Beta Bionics) ......................... .............................................. 25  
1.3.3 Fiasp (Novo Nordisk) ........................ ................................................... ....................................... 28  
1.4 Potential Risks and Benefits of the Investigati onal Device and Study Participation ............... ......... 28  
1.4.1 Known Potential Risks ....................... ................................................... ...................................... 29  
[IP_ADDRESS] Venipuncture Risks ........................ ................................................... .................................. 29  
[IP_ADDRESS] Fingerstick Risks ......................... ................................................... ..................................... 29  
[IP_ADDRESS] Subcutaneous Catheter Risks (CGM) ......... ................................................... ..................... 29  
[IP_ADDRESS] Risk of Hypoglycemia ...................... ................................................... ............................... 29  
[IP_ADDRESS] Risk of Hyperglycemia ..................... ................................................... ............................... 29  
[IP_ADDRESS] Questionnaires ............................ ................................................... ...................................... 30  
[IP_ADDRESS] Other Risks ............................... ................................................... ........................................ 30  
1.4.2 Known Potential Benefits .................... ................................................... ..................................... 30  
1.4.3 Risk Assessment ............................. ................................................... .......................................... 30  
1.5 General Considerations......................... ................................................... .......................................... 31  
CHAPTER 2:  PARTICIPATION ENROLLMENT AND STUDY INITIATION  .................................................. . [ADDRESS_319992] Period .................................. ................................................... ............................................. 33  
2.2.2 Transition Phase ............................ ................................................... ........................................... 34  
2.3 Eligibility and Exclusion Criteria ............ ................................................... ....................................... 34  
2.3.1 Eligibility ................................. ................................................... ................................................. 3 4  
2.4 Eligibility Assessment and Baseline Data Collec tion .............................................. ......................... 36  
2.5 Historical Information ........................ ................................................... ............................................ 37  
2.6 Screening Testing and Procedures .............. ................................................... .................................... 37  
2.7 Baseline CGM Data Collection .................. ................................................... .................................... 37  
2.8 Screen Failures ............................... ................................................... ................................................ 38  
CHAPTER 3:  RCT  RANDOMIZATION VISIT AND START UP .................................................. .................. 39  
3.1 Timing of Visit ............................... ................................................... ................................................ 39  
3.2 Testing and Procedures ........................ ................................................... ........................................... 39  
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  PAGE 5 OF 97 3.3 Randomization ................................. ................................................... ............................................... 40  
3.4 Study Procedures for the Control Group ........ ................................................... ................................ 40  
3.5 Study Procedures for the BP Group ............. ................................................... .................................. 40  
CHAPTER 4:  RCT  OUTPATIENT STUDY PROCEDURES  .................................................. .......................... 42  
4.1 Outpatient Procedures for Both Groups ......... ................................................... ................................ 42  
4.1.1 Resources for Participants .................. ................................................... ...................................... 42  
4.1.2 Weekly At-Home Questionnaire ................ ................................................... .............................. 42  
4.2 Outpatient Procedures for Control Group........ ................................................... ............................... 42  
4.3 Outpatient Procedures for BP Group ............ ................................................... .................................. 43  
CHAPTER 5:  RCT  FOLLOW -UP STUDY VISITS  .................................................. ....................................... 47  
5.1 Timing of Visits .............................. ................................................... ................................................ 47  
5.2 Procedures at Phone Contacts and Follow-up Visi ts ................................................ ......................... 47  
5.2.1 Phone Contacts .............................. ................................................... ........................................... 47  
5.2.2 Clinic Visits ............................... ................................................... ............................................... 47  
5.3 Evaluation of Control Group for Extension Study  .................................................. .......................... 48  
5.4 Transition Phase .............................. ................................................... ............................................... 48  
CHAPTER 6:  TRANSITION PHASE  .................................................. ................................................... ......... 49  
6.1 Participants .................................. ................................................... ...................................................  49  
6.2 Randomization ................................. ................................................... ............................................... 49  
6.3 iLet BP Guidance............................... ................................................... ............................................. 49  
6.4 Visits ........................................ ................................................... ................................................... .... 49  
CHAPTER 7:  STUDY DRUGS AND DEVICES  .................................................. ............................................. 50  
7.1 Study Drugs ................................... ................................................... ................................................. 5 0  
7.2 Study Devices ................................. ................................................... ................................................ 50  
7.2.1 iLet Infusion Sets .......................... ................................................... ............................................ 50  
7.2.2 iLet Ready-to-Fill Insulin Cartridges ....... ................................................... ................................ 50  
7.2.3 Continuous Glucose Monitors ................. ................................................... ................................. 50  
[IP_ADDRESS] Dexcom G6 CGM ............................. ................................................... ............................... 51  
7.2.4 iLet Bionic Pancreas ........................ ................................................... ......................................... 51  
7.2.5 Contour Next Glucometer ..................... ................................................... ................................... 52  
7.2.6 Precision Xtra Blood Ketone Meter ........... ................................................... .............................. 52  
7.3 Participant Access to Study Device at Study Clo sure .............................................. ......................... 52  
CHAPTER 8:  LABORATORY TESTING , QUESTIONNAIRES AND FOCUS GROUP  ...................................... 53  
8.1 Laboratory Testing ............................ ................................................... ............................................. 53  
8.2 Questionnaires ................................ ................................................... ................................................ 53  
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  PAGE 6 OF 97 8.2.1 Introduction ................................ ................................................... .............................................. 53  
8.2.2 Brief Description of Questionnaires ......... ................................................... ................................ 53  
8.3 Focus Groups .................................. ................................................... ................................................ 55  
Focus Groups ...................................... ................................................... ............................................... 55  
CHAPTER 9:  UNANTICIPATED PROBLEMS , ADVERSE EVENTS , AND DEVICE  ISSUE REPORTING  ........ 57  
9.1 Unanticipated Problems ........................ ................................................... .......................................... 57  
9.2 Adverse Events ................................ ................................................... ............................................... 57  
9.2.1 Definitions ................................. ................................................... ............................................... 57  
9.2.2 Reportable Adverse Events ................... ................................................... ................................... 58  
9.2.3 Hypoglycemic Events ......................... ................................................... ...................................... 59  
9.2.4 Hyperglycemic/Ketotic Events ................ ................................................... ................................. 59  
9.2.5 Relationship of Adverse Event to Study Device  .................................................. ....................... 60  
9.2.6 Severity (Intensity) of Adverse Events ...... ................................................... ............................... 60  
9.2.7 Expectedness ................................ ................................................... ............................................ 60  
9.2.8 Coding of Adverse Events .................... ................................................... .................................... 60  
9.2.9 Outcome of Adverse Events ................... ................................................... .................................. 61  
9.3 Reportable Device Issues ...................... ................................................... .......................................... 61  
9.4 Timing of Event Reporting ..................... ................................................... ........................................ 62  
9.5 Reporting to Novo Nordisk ..................... ................................................... ....................................... 62  
9.6 Safety Oversight .............................. ................................................... ............................................... 63  
9.7 Stoppi[INVESTIGATOR_2121] ............................. ................................................... ............................................... 63  
9.7.1 Criteria for Suspending or Stoppi[INVESTIGATOR_171643] S tudy .............................................. ....................... 64  
CHAPTER 10:  MISCELLANEOUS CONSIDERATIONS  .................................................. ............................... 65  
10.1 Collection of Medical Conditions and Medicatio ns ................................................ ........................ 65  
10.2 Prohibited Medications, Devices, Treatments an d Procedures ...................................... .................. 65  
10.3 Rescue Medications ........................... ................................................... ........................................... 65  
10.4 Pregnancy Reporting .......................... ................................................... .......................................... 65  
10.5 Participant Compensation ..................... ................................................... ........................................ 65  
10.6 Participant Withdrawal ....................... ................................................... .......................................... 66  
10.7 Confidentiality .............................. ................................................... ................................................ 66  
CHAPTER 11:  STATISTICAL CONSIDERATIONS  .................................................. ...................................... 67  
11.1 Statistical and Analytical Plans ............. ................................................... ....................................... 67  
11.2 Statistical Hypotheses ....................... ................................................... ............................................ 67  
11.3 Sample Size .................................. ................................................... ................................................ 67  
11.4 Efficacy Outcome Measures .................... ................................................... ..................................... 68  
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  PAGE 7 OF 97 11.4.1 Primary and Key Secondary Efficacy Endpoints  .................................................. .................... 68  
11.4.2 Additional Secondary Efficacy Endpoints .... ................................................... ......................... 68  
[IP_ADDRESS] Secondary Efficacy Endpoints Included in H ierarchical Analysis .............................. ..... 68  
[IP_ADDRESS] Other Secondary Efficacy Endpoints ....... ................................................... ...................... 68  
11.5 CGM Metrics Calculations ..................... ................................................... ...................................... 70  
11.6 Analysis of the Primary and Secondary Efficacy  Endpoints ........................................ ................... 70  
11.6.1 HbA1c Analyses (Superiority) ............... ................................................... ................................ 70  
11.6.2 Time <54 mg/dL (Noninferiority) ............ ................................................... .............................. 71  
11.6.3 Secondary CGM Metrics (Superiority) ........ ................................................... .......................... 71  
11.6.4 Hierarchical Analyses ...................... ................................................... ....................................... 71  
11.6.5 Questionnaires and Other Outcomes Analyses . ................................................... ..................... 72  
11.7 Safety Analyses .............................. ................................................... .............................................. 72  
11.7.1 Safety Tabulations Specific to the BP Group ................................................... ......................... 73  
11.8 Additional Tabulations and Analyses .......... ................................................... ................................. 73  
11.8.1 Tabulations Specific to the BP Group ....... ................................................... ............................. 73  
11.9 Planned Interim Analyses ..................... ................................................... ........................................ 73  
11.10 Subgroup Analyses ........................... ................................................... .......................................... 73  
11.11 Multiple Comparison/Multiplicity ............ ................................................... .................................. 74  
11.12 Additional Exploratory Analyses ............. ................................................... .................................. 74  
11.13 BP Fiasp Versus Control Group ............... ................................................... .................................. 74  
11.14 Comparison of Aspart/Lispro Group and Fiasp G roup .............................................. ................... 75  
11.15 Transition Phase ............................ ................................................... ............................................. 75  
CHAPTER 12:  DATA COLLECTION AND MONITORING  .................................................. .......................... 76  
12.1 Case Report Forms and Other Data Collection .. ................................................... .......................... 76  
12.2 Study Records Retention ...................... ................................................... ........................................ 76  
12.3 Quality Assurance and Monitoring ............. ................................................... .................................. 76  
12.4 Protocol Deviations .......................... ................................................... ............................................ 77  
CHAPTER 13:  ETHICS /P ROTECTION OF HUMAN PARTICIPANTS  .................................................. .......... [ADDRESS_319993] ............................. ................................................... ............................................... 78  
13.2 Institutional Review Boards .................. ................................................... ....................................... 78  
13.3 Informed Consent Process ..................... ................................................... ....................................... 78  
13.3.1 Consent Procedures and Documentation ....... ................................................... ......................... 78  
13.3.2 Participant and Data Confidentiality ....... ................................................... ............................... 78  
13.3.3 Future Use of Data.......................... ................................................... ........................................ 79  
13.3.4 Future Use of Biologic Samples ............. ................................................... ................................ 79  
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  PAGE 8 OF 97 CHAPTER 14:  ANCILLARY STUDY TO TEST THE I LET WITH INPUTTED BLOOD GLUCOSE 
MEASUREMENTS  .................................................. ................................................... ................................... 80  
14.1 Objective .................................... ................................................... ...................................................  80  
14.2 Sample Size .................................. ................................................... ................................................ 80  
14.3 Eligibility Criteria ......................... ................................................... ................................................ 80  
14.4 Study Protocol ............................... ................................................... ............................................... 80  
14.5 Outcomes and Analysis Plan ................... ................................................... ..................................... 81  
14.6 Safety Monitoring ............................ ................................................... ............................................. 81  
APPENDIX A:  PRIOR STUDIES CONDUCTED USING THE BIONIC  PANCREAS  SYSTEM  .......................... [ADDRESS_319994] Randomized Controlled/Clinical Trial 
SADE Serious Adverse Device Event 
SAE Serious Adverse Event 
SAP Statistical Analysis Plan 
SC Subcutaneous 
SD Standard Deviation 
SGLT2 Sodium Glucose Cotransporter [ADDRESS_319995] 
UI User Interface 
 
 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 11  OF 97 PROTOCOL SUMMARY  
 Description 
Title The Insulin-Only Bionic Pancreas Pi[INVESTIGATOR_243897]: Tes ting the iLet in Adults and 
Children with Type 1 Diabetes  
Précis This multi-center randomized control trial (RCT) wi ll compare efficacy and 
safety endpoints using the insulin-only configurati on of the iLet Bionic 
Pancreas (BP) System versus a control group using C GM during a 13-week 
study period. Participants may be enrolled initiall y into a screening protocol 
and then transfer into the RCT protocol, or they ma y enter directly into the 
RCT protocol.  At the completion of use of the BP system (end of R CT for BP 
Group), participants will enter a 2–4 day Transitio n Phase and be randomly 
assigned to either transition back to their usual m ode of therapy (MDI or pump 
therapy) based on therapeutic guidance from the iLe t BP System or transition 
back to their usual mode of therapy based on what t heir own insulin regimens 
were prior to enrolling in the RCT. 
Investigational Device iLet Bionic Pancreas System, which consists of an i ntegrated infusion pump, 
touchscreen display, Bluetooth radio, and insulin d osing algorithms, that 
automatically controls insulin delivery based on gl ucose values obtained by 
[CONTACT_179283] a Dexcom G6 sensor. 
Objectives Primary Objective 
• To compare the efficacy and safety of the insulin-o nly configuration of 
the iLet BP System using insulin lispro, insulin as part, and Fiasp (adults 
only) in maintaining near-normal glycemia relative to usual care in a 
home-use study in adults and children with T1D. 
Secondary Objectives 
• To assess the impact of the insulin-only configurat ion of the iLet BP 
System on quality of life and treatment satisfactio n. 
Study Design Randomized clinical trial followed by a Transition Phase for those using the 
iLet BP System 
Number of Sites ~[ADDRESS_319996] The primary analysis will include both the pediatri c and adult participants in a 
single analysis.  BP aspart/lispro Group and BP Fia sp Group will be compared 
separately with the Control Group. 
Superiority for HbA1c at 13 weeks will be considere d the primary endpoint. 
Non-inferiority for time <54 mg/dL measured with CG M at intervals over the 
13 weeks (pooled for analysis) will be considered a  key secondary endpoint. 
To preserve the overall type 1 error, a hierarchica l gatekeepi[INVESTIGATOR_263200]. If a comparison results in a statistically significant 
result (p < 0.05 for superiority testing and <0.025  for one-sided non-inferiority 
testing), then testing will proceed to the next one  on the list. 
The order of testing will be as follows: 
1.  HbA1c at 13 weeks (superiority) 
2.  CGM time < 54 mg/dl (non-inferiority) 
Superiority for the following CGM metrics 
3.  Mean glucose 
4.  Time 70-180 mg/dL 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 12  OF 97  Description 
5.  Time >180 mg/dL 
6.  Time >250 mg/dL 
7.  Standard deviation 
8.  Time <70 mg/dL 
9.  Time <54 mg/dL 
10.  Coefficient of variation 
Key Safety Outcomes: 
• severe hypoglycemia 
• diabetic ketoacidosis 
• other serious adverse events 
Other Key Outcomes: 
• quality of life questionnaires 
Eligibility Criteria Eligibility may be assessed initially in a separate  screening protocol or at a 
screening visit in the RCT protocol.  To be eligible for all phases of the study, 
a participant must meet all of the following inclus ion criteria and none of the 
exclusion criteria: 
Inclusion  
1.  Clinical diagnosis of T1D for at least one year and  using insulin for at 
least 1 year 
2.  Diabetes managed using the same regimen (either pum p or MDI, 
with or without CGM) for ≥ 3 months prior to collection of CGM 
data (either from personal Dexcom G6 device or blin ded G6 device) 
3.  Age ≥ [ADDRESS_319997] 4 weeks (according to 
judgment of investigator if meter is not available) . 
5.  Willingness not to start any new non-insulin glucos e-lowering agent 
during the course of the trial 
6.  For participants <18 years old, living with one or more parent/legal 
guardian knowledgeable about emergency procedures f or severe 
hypoglycemia.  
7.  For participants >18 years old who live alone, part icipant has a 
relative or acquaintance who lives within 30 minute s of participant 
and is willing to be contact[CONTACT_263216] a medical  emergency and 
can’t be reached. 
8.  Investigator believes that the participant can safe ly use the iLet and 
will follow the protocol 
• The investigator will take into account the partici pant’s 
HbA1c level, compliance with current diabetes manag ement, 
and prior acute diabetic complications. For this re ason, 
there is no upper limit on HbA1c specified for elig ibility. 
9.  If a GLP-[ADDRESS_319998] be 
willing to discontinue use while the iLet BP system  is being used. 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 13  OF 97  Description 
Exclusion  
1.  Unable to provide informed consent (e.g. impaired c ognition or 
judgment) 
2.  Unable to safely comply with study procedures and r eporting 
requirements (e.g. impairment of vision or dexterit y that prevents 
safe operation of the bionic pancreas, impaired mem ory) 
3.  Unable to speak and read English 
•  For pediatric participants, both caregivers and pa rticipants 
must be able to speak and read English 
4.  Plan to change usual diabetes regimen in the next 3  months 
• This would include changing from MDI to pump.  pump  to MDI, 
change in insulin automation delivery system, start ing a CGM if 
not previously used, changes in drug therapy specif ically for 
glucose control except for changes in one insulin a nalog to 
another.  
o Changes in insulin dose, carb ratio, sensitivity fa ctor and 
basal rate profile are allowed. 
5.  Current use of non-FDA approved closed-loop or hybr id closed-loop 
insulin delivery system 
6.  Use of Api[INVESTIGATOR_263201]-study rapid-acting insulin  analog and 
unwilling to switch to lispro or aspart for the dur ation of the study 
7.  Known hemoglobinopathy (sickle cell trait is not an  exclusion) 
8.  Current participation in another diabetes-related c linical trial 
9.  History of cystic fibrosis, pancreatitis, or other pancreatic disease, 
including pancreatic tumor or insulinoma, or histor y of complete 
pancreatectomy 
10.  Electrically powered implants (e.g. cochlear implan ts, 
neurostimulators) that might be susceptible to RF i nterference 
11.  Established history of allergy or severe reaction t o adhesive or tape 
that must be used in the study 
12.  Current use of SGLT2 inhibitors or a sulfonylurea d rug ( use more 
than 3 months prior to enrollment is acceptable ) 
• If using GLP1 agonist, pramlintide, or metformin dr ugs must be 
on a stable dose for 3 months prior to enrollment ( and as per 
inclusion criterion #8, must be willing to disconti nue use of 
GLP-[ADDRESS_319999]).  
13.  Pregnant (positive urine hCG), breast feeding, plan  to become 
pregnant in the next 3 months, or sexually active w ithout use of 
contraception  
• If the visit is conducted virtually, a pregnancy te st will be 
provided to the participant and verbal report of th e result will be 
acceptable 
14.  For adults >[ADDRESS_320000] recent (must be with in the last 2 years) 
eGFR <30 ml/min; OR currently in renal failure on d ialysis  
• If no eGFR is available for an adult participant du ring the last [ADDRESS_320001] be obtained to confirm eligibility 
15.  Presence of a medical condition or use of a medicat ion that, in the 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 14  OF 97  Description 
judgment of the investigator, clinical protocol cha ir, or medical 
monitor, could compromise the results of the study or the safety of 
the participant.  Conditions to be considered by [CONTACT_3433] e investigator may 
include the following: 
• Alcohol or drug abuse 
• Use of prescription drugs that may dull the sensori um, reduce 
sensitivity to symptoms of hypoglycemia, or hinder decision 
making during the period of participation in the st udy  
• Coronary artery disease that is not stable with med ical 
management, including unstable angina, angina that prevents 
moderate exercise (e.g. climbing a flight of stairs ) despi[INVESTIGATOR_263202], or within the last 12 months be fore 
screening a history of myocardial infarction, percu taneous 
coronary intervention, enzymatic lysis of a presume d coronary 
occlusion, or coronary artery by[CONTACT_15806]  
• Congestive heart failure with [LOCATION_001] Heart Associ ation 
(NYHA) Functional Classification III or IV  
• History of TIA or stroke in the last 12 months 
• Untreated or inadequately treated mental illness  
• History of eating disorder within the last 2 years,  such as 
anorexia, bulimia, or diabulemia or omission of ins ulin to 
manipulate weight 
• History of intentional, inappropriate administratio n of insulin 
leading to severe hypoglycemia requiring treatment 
16.  Employed by, or having immediate family members emp loyed by 
[CONTACT_263217], or being directly involved in conduct ing the clinical 
trial, or having a direct supervisor at place of em ployment who is also 
directly involved in conducting the clinical trial (as a study 
investigator, coordinator, etc.); or having a first -degree relative who 
is directly involved in conducting the clinical tri al 
 
Sample Size RCT Period:  ~ 440 participants (165 participants 6–<18 years a nd 275 
participants  ≥18 years) 
Transition Phase for All Participants on Completion  of BP Use:  up to 
~440 participants  (up to ~165 pediatric participan ts and ~275 adult 
participants) 
Treatment Groups Pediatric (6-<18 years old) RCT Pe riod:  Random assignment in a 2:1 ratio 
to the BP Group (with lispro or aspart) or the Cont rol Group (~110 and ~55 
participants, respectively) for a period of [ADDRESS_320002].  
Adult (≥18 years) RCT Period:  Random assignment in a 2:2:1 ratio to the 
BP Group (with lispro or aspart), the BP Fiasp Grou p, or the Control Group 
(~110, 110, and 55 participants, respectively) for a period of [ADDRESS_320003]. 
Transition Phase  (all adult and pediatric participants at end of RC T [BP 
Group] : random assignment in a 1:1 ratio to transition bac k to either 
participant’s usual therapy or the dosing recommend ations from the iLet BP. 
Participant Duration ~3 months 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 15  OF 97  Description 
Protocol Overview/Synopsis The study has two major parts: (1) the RCT Period, and (2) the Transition 
Phase. These parts are described below and detailed  in the main part of the 
protocol.  
The 13-week, parallel-group, multi-center RCT Perio d is designed to compare 
the insulin-only iLet BP Group using insulin lispro , insulin aspart, or Fiasp 
(adults only); and a control group using CGM (Contr ol Group).  Upon 
completion of the RCT Period, the BP Group will ent er the 2–4 day Transition 
Phase and eligible participants in the Control Grou p will be offered 
participation in a separate Extension Study. 
A 2–[ADDRESS_320004] Period (BP Gr oup).  Participants will 
be randomly assigned (1:1) to either transition bac k to their usual mode of 
therapy (MDI or pump therapy) based on therapeutic guidance from the iLet 
BP system or transition back to their usual mode of  therapy based on what 
their own insulin regimens were prior to enrolling in the RCT Period. For 
those randomized to using their pre-study regimens,  the dosing can be 
adjusted by [CONTACT_263218]-
study regimen as closely as possible.  
 
Protocol Overview/Synopsis 
(continued) RCT Period Visit and Phone Contact [CONTACT_263219] 
• Screening Visit (which may be completed as part of a separate 
screening protocol) 
 – Eligibility assessed, informed consent signed, p oint-of-care/local 
HbA1c, psychosocial questionnaires completed, basel ine Dexcom G6 
CGM data collection. 
o For baseline data collection, participants using a personal 
Dexcom G6 who have at least 85% of possible glucose  data 
in last 14 days can skip the CGM data collection 
o Participants using a personal Dexcom G6 with <85% o f data 
will use their personal Dexcom G6. 
o Participants using a personal Dexcom G5 will be pro vided 
with an unblinded Dexcom G6 for CGM data collection . 
o Participants who do not use a Dexcom G5 or G6 will be 
provided with a blinded Dexcom G6 for CGM data 
collection.  
o For participants who completed the separate screeni ng 
protocol, eligibility will be reassessed.  Particip ants will not 
need to repeat the point-of-care/local HbA1c, psych osocial 
questionnaires or CGM data collection.   
• If the separate screening protocol was completed or  CGM data collection 
is not needed, randomization can proceed immediatel y.  If CGM data 
collection was performed as part of this protocol, randomization visit 
will occur14-21 days after screening.  
• Prior to randomization, eligibility will be reasses sed and blood collected 
for central lab HbA1c 
• BP study start/Control study start on day of Random ization Visit 
• Phone contacts after 1-2 days and 7 (±2) days 
• Visits at 2 weeks (±4 days), 6 weeks (±4 days), 10 weeks (±4 days), and 
~13 weeks (91–98 days from randomization): 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE [ADDRESS_320005] phase.  
o At the 6-week and 13-week visits, central lab HbA1c  
determination and psychosocial questionnaires 
Transition Phase Visit Schedule 
• Randomization and transition to usual care regimen at 13-week visit for 
BP Group, for a period of 2–4 days in duration. 
• Visit 2-[ADDRESS_320006] Period 
Transition Phase Peds < 18 yo 
2 equal age groups 
N=165 
BP 
N=110 Adults ≥ 18 
N=275 
Control 
N=55 Control 
N=55 BP-F
N=110 BP-LA 
N=110 
Transition Phase 
N=330 (max) 
iLet 
Recommendations 
N=165 Usual Care Transition 
N=[ADDRESS_320007] Period 
 Screening Randomization/ 
Study Start (0w)  1-2d 
(phone 
call) 1w 
(phone 
call) 2w 6w 10w 13w 
Informed Consent X        
Eligibility 
assessment X X       
Hypoglycemia 
Unawareness 
Assessment X       X 
HbA1c point of 
care/local lab [ADDRESS_320008] 2 X X 6   X X X  
Height/Weight X X6     X  X 
Psychosocial 
questionnaires [ADDRESS_320009]-menarche and pre-menopausal  women with child-bearing potential 
3Questionnaires (See Chapter 8) 
4At screening, CGM wear can be skipped for the purpo se of collection of baseline data by [CONTACT_263220] G6 sensor 
with at least 85% usage in last [ADDRESS_320010] stopped using the iLet BP system an d Dexcom G6 CGM 
and agree to wear a Dexcom G6 sensor. 
5For participants who use a Dexcom G6 CGM 
6 If randomization date is different from screening date 
7 If not completed as part of separate screening prot ocol 
8 Study visits can occur in clinic or virtually 
9 Will be skipped if visit is conducted virtually 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 19  OF 97 Table 2. Schedule of Study Visits 2 and Procedures During the Transition Phase 
 Randomization/ 
Study Start (0d)  2-4d 
Questionnaire 1   X 
Placement of CGM sensor  (if not 
already wearing one) X   
Data download   X 
Adverse event querying   X 
1Customized questionnaire (See Section 8.2.1) 
2Study visits can occur in clinic or virtually 
 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 20  OF 97 Chapter 1:  Introduction 1 
1.1  Background and Rationale 2 
Maintaining near-normal blood glucose (BG) levels ( 70–120 mg/dl) is a challenging and 3 
critically important task for people with type 1 di abetes (T1D).  The Diabetes Control and 4 
Complications Trial (DCCT) Research Group definitiv ely demonstrated that tight BG control 5 
can reduce long-term complications.  The likelihood  and severity of nephropathy, retinopathy, 6 
neuropathy, macrovascular disease, and skin disorde rs is reduced in proportion to reductions in 7 
glycated hemoglobin (HbA1c), which is closely corre lated with long-term average BG levels.  8 
Risks for such complications are elevated by [CONTACT_14774]-  to five-fold with diabetes.  On the other hand, 9 
tight BG control through conventional intensive ins ulin therapy increases the likelihood of 10 
epi[INVESTIGATOR_179264], which carries acute risks, i ncluding convulsions, seizures, coma, and 11 
death. Conventional therapy also requires a relentl ess daily effort to count carbohydrates, 12 
frequently monitor BG throughout the day and night,  and administer a daily insulin regimen. 13 
A more reliable method for achieving consistent BG control consists of an integrated artificial 14 
or bionic pancreas (BP) system, consisting of a con tinuous glucose monitor (CGM), an infusion [ADDRESS_320011] seen the development of several c ompeting strategies for automated or semi- 19 
automated management of glycemia. One large differe nce between competing designs is whether 20 
they use insulin alone (insulin-only) and rely on t he user treating with carbohydrates if the blood 21 
glucose falls too low, or insulin and glucagon (bih ormonal) and use glucagon to automatically [ADDRESS_320012].  Therefore, 30 
people with T1D are functionally glucagon deficient . 31 
An important challenge for automated glucose contro l is that the physiologic need for 32 
insulin can change rapi[INVESTIGATOR_375], but insulin is slowly a bsorbed when delivered subcutaneously.  33 
Even “rapid-acting” insulin analogs such as insulin  lispro (Humalog) have a mean time-to-peak 34 
of ~[ADDRESS_320013] to insulin, 36 
glucagon is absorbed quickly, with a time-to-peak o f ~15-20 minutes.  Therefore, small doses of 37 
glucagon can be given to counter the effects of exc ess insulin that has already been delivered and 38 
cannot be withdrawn, and can prevent hypoglycemic e vents that could not be prevented by 39 
suspending insulin delivery alone.  This allows the  BP to ask less of the user (less need to 40 
respond to alarms, take carbohydrates to treat hypo glycemia) and allows the user to be more 41 
spontaneous (no need to announce exercise in advanc e). [ADDRESS_320014] began developi[INVESTIGATOR_263203], 48 
there were no stable glucagon formulations or gluca gon analogs available.  However, Zealand 49 
Pharma’s development program for its glucagon analo g (dasiglucagon) is now sufficiently [ADDRESS_320015] inpatient study of the 54 
BP in adults and adolescents during over 2,300 pati ent-hours of exposure, frequent blood 55 
sampling showed that the aggregate mean glucagon le vels were in the normal fasted range 56 
(<150 pg/ml by [CONTACT_263221]) betw een 61% and 91% of the time and 57 
exceeded 400 pg/ml on only 4 occasions, all of whic h were transient.  In the glucagonoma 58 
syndrome, clinically evident cases are associated w ith glucagon levels chronically in excess of 59 
1,000 pg/ml. A review of case series suggests that glucagonomas and other neuroendocrine 60 
tumors producing chronic glucagon levels <400 pg/ml  are usually discovered incidentally on [ADDRESS_320016] been shown to be safe i n pre-clinical studies.  In our home use Bionic 64 
Pancreas Multi-Center Study (BPMC), mean glucagon u sage on the BP was 7 mcg/kg/day.  65 
Doses of glucagon up to 9 mg/kg/day (1,286-fold hig her) have been administered to rats, rabbits, 66 
cats, and dogs for 6 months without any toxic effec ts or weight loss.  In rats and beagle dogs 67 
given up to 4 mg/kg/day and 0.2 mg/kg, respectively  (571-fold and 29-fold higher than our BP 68 
doses, respectively), the only changes were increas es in serum glucose and a small increase in [ADDRESS_320017] developed an autonomous, self-learning BP t hat requires only the participant's weight 78 
for initialization, and then autonomously adapts, m odestly or dramatically, as needed, to cope 79 
with the wide range of insulin requirements of adul ts, adolescents, and pre-adolescents with 80 
T1D.  Our BP obviates the need for the patient to k now, or even appreciate, their insulin 81 
requirements, and renders obsolete any need for pat ients or caregivers to know 82 
carbohydrate-to-insulin ratios, basal rates, or ins ulin correction factors. 83 
Our core technology is our suite of three mathemati cal dosing algorithms for insulin infusion, 84 
which orchestrates all subcutaneous (SC) insulin do sing.  At its centerpi[INVESTIGATOR_148062] a model-predictive 85 
control (MPC) algorithm, which bases insulin doses on the glucose data and insulin absorption [ADDRESS_320018] to incorporate insulin  pharmacokinetics (PK) into our algorithm, by 87 
augmenting it with a mathematical formulation for e stimating the concentration of insulin in the 88 
blood and predicting its future concentration.  It is essential to compensate for the slow 89 
absorption rate of SC insulin analogs (peak time in  blood of 30–90 min, clearance in 4–8 hr), and 90 
to enable the algorithm to refrain from stacking an d overdosing insulin.  Furthermore, our MPC 91 
algorithm automatically adjusts its insulin-doing a ggressiveness continuously and in real time to 92 
different insulin needs between individuals and var iable needs within the same individual.  93 
Running in parallel with our MPC algorithm is an al gorithm that automatically modulates basal 94 
insulin delivery over multiple time scales, and ano ther algorithm that automatically adapts 95 
insulin doses in response to optional meal announce ments.  Unlike current insulin pumps, and 96 
all of the insulin-only control algorithms of which  we are aware, our adaptive basal insulin 97 
algorithm obviates the need for the user to set, or  even know, his or her “basal-rate profile”.  98 
Instead, it is capable of automatically adapting to , and compensating for, changes in an 99 
individual's basal insulin need, such as might occu r over a period of hours, days, or weeks 100 
(e.g. circadian hormonal fluctuations, intercurrent  illness, physical activity, or emotional state) 101 
or as might occur over a period of months or years due to developmental changes (e.g. hormonal 102 
changes that occur during puberty or menopause).  O ur adaptive meal dose controller obviates 103 
the need for the user to set, or even know, his or her “carbohydrate-to-insulin ratios,” as it 104 
makes automatic adjustments based on dosing history  for similar meal announcements made on 105 
previous days, and customizes the dose for each ind ividual and for time of day.  Our BP also 106 
includes a proportional-derivative (PD) algorithm g overning SC micro-doses of glucagon to help 107 
prevent impending hypoglycemia.  Glucagon dosing is  based on the glucose level and rate of 108 
descent. It could occur preemptively even if glucos e is above range and it includes a feedback 109 
term to account for the pending effects of recent g lucagon doses.  The amount of glucagon dosed 110 
also feeds back on the insulin controller, so that large amounts of glucagon dosing decrease the 111 
aggressiveness of the insulin controller. 112 
Taken together, these mathematical algorithms provi de a universal framework for a glycemic 113 
control strategy that requires no quantitative inpu t from, or participation by, the user (besides 114 
entering body weight to initialize the system), but  which automatically adapts insulin and [ADDRESS_320019] met is 116 
enabling our technology to remain completely autono mous in managing insulin and glucagon 117 
delivery even when the CGM is offline.  Specificall y, when the CGM is offline, our BP invokes 118 
the high-resolution “basal rate profile” that it ha d recently learned and stored when the CGM was 119 
online.  On the basis of what the system learned an d stored about meal announcements when the 120 
CGM was online, it is able to respond to meal annou ncements in the same manner when the 121 
CGM is offline.  Finally, it automatically responds  to user-entered BG values when the CGM is 122 
offline by [CONTACT_179296] a correction dose of insulin or glucagon based on what it learned about the 123 
user's insulin and glucagon needs when the CGM was online.  Thus, our BP never relies on, or [ADDRESS_320020] 131 
glucose target that can be chosen by [CONTACT_28024] (towa rds which the insulin controller drives down 132 
the blood glucose levels) is increased from 100 mg/ dl in the bihormonal system to 110 mg/dl in [ADDRESS_320021] of reducing insulin dosing more in the i nsulin-only configuration than in the 144 
bihormonal configuration and leads to a higher aver age glucose achieved by [CONTACT_263222]-only 145 
configuration than the bihormonal configuration for  the same glucose target.    146 
The intended use for the insulin-only configuration  of the BP system is to provide automated 147 
glucose control prior to commercial availability of  a stable glucagon analog. It may also be used 148 
for people for whom goals for therapy can be achiev ed with minimal hypoglycemia and/or use of 149 
oral carbohydrates without the use of glucagon. Thi s may include people with type 2 diabetes or 150 
cystic fibrosis-related diabetes. 151 
1.3.1  iPhone-Based BP System 152 
Our BP hardware platform began as a laptop-driven s ystem, which we used in all of our inpatient 153 
studies (between 2008–2012) at MGH.  In late 2012, we received FDA approval to conduct our [ADDRESS_320022] outpatient study using our new mobile wearabl e iPhone-Based BP System, which we used 155 
in all of our outpatient and home-use studies betwe en 2013 and 2017.  The system consisted of 156 
one or two (depending on the configuration of the s ystem) t:slim infusion pumps (Tandem), a 157 
G4 Platinum AP CGM (Dexcom), and the BP insulin-dos ing and glucagon-dosing control 158 
algorithms.  The control algorithms were encoded in  an app together with a simple graphical user 159 
interface (GUI) that ran on an iPhone 4S (Apple).  The iPhone and the Dexcom CGM receiver 160 
were connected through their external communication  ports with a custom hardware interface 161 
and were housed together in a custom enclosure.  Th e iPhone, CGM, and enclosure together 162 
comprised our BP Control Unit.  The BP app ran the insulin-dosing and glucagon-dosing control 163 
algorithms, managed connectivity between the iPhone  and the Dexcom receiver, and controlled 164 
the Bluetooth radio, which effectuated communicatio n between the iPhone and the t:slim pump.  165 
The GUI displayed the current CGM glucose, the CGM trend, and the insulin and glucagon 166 
doses.  The BP app also provided the interface to i nput meal announcements.  Meal announce- 167 
ments (1) specified a type of meal (as “breakfast,”  “lunch,” or “dinner”) (2) designated the size 168 
of the meal (as “larger than typi[INVESTIGATOR_2855],” “typi[INVESTIGATOR_2855],” “ smaller than typi[INVESTIGATOR_2855],” or “just a bite”), and 169 
(3) triggered a partial meal-priming bolus, the siz e of which automatically adapts during the 170 
course of the trial to meet a target of 75% of the insulin required for that size and type of meal. [ADDRESS_320023] as if they were CGM 174 
values.  The GUI also displayed visual alarms assoc iated with an audio signal if communication 175 
was dropped between the BP app and the t:slim pump,  or if the CGM glucose was below a low [ADDRESS_320024] conducted over 1 10 outpatient experiments of 5–11 days 179 
in duration in each participant with T1D (> 800 pat ient days or > 2 patient years of data), and [ADDRESS_320025] that the average 182 
total daily dose of insulin among these participant s varied by [CONTACT_46431] 13-fold (from 11 to 145 183 
units/day) among children and adults with T1D. [ADDRESS_320026] 
supervision Adults 21 and older, 
randomized crossover 
with usual care 
(at home)  
[ADDRESS_320027] 
Insulin-
only Study  Outpatient, 
unsupervised 
at home  16  2 arms, 
7 days 
each  Insulin-only  Remote 
telemetric 
monitoring  Adults aged 18 and 
older, compared 
with usual care  
7 2017  Monitoring 
Study  Outpatient, 
unsupervised 
at home  23  4 arms, 
7 days 
each  Bihormonal 
and Insulin-
only  Each arm 
repeated 
with and 
without 
remote 
telemetric 
monitoring  Adults aged 18 and 
older, compared 
with usual care with 
and without remote 
monitoring  
8 2017  Zealand 
Feasibility 
Study  Supervised, 
in clinic  12  2 arms, 
8 hours 
each  Bihormonal  N/A  Adults aged 18 and 
older, randomized 
crossover comparing 
Eli Lilly glucagon 
with dasiglucagon in 
structured clinic 
setting  
1.3.2  Fully Integrated iLet ®  BP System (Beta Bionics)  197 
The iLet ® Bionic Pancreas System (iLet), developed by [CONTACT_192763] B ionics, Inc., is a wearable device 198 
that autonomously manages glycemia in people with d iabetes and other conditions of glycemic 199 
dysregulation.  The iLet integrates CGM technology (choice of either Dexcom G6 or Senseonics 200 
Eversense) via its built-in Bluetooth radio.  It in cludes two independent motor–drivetrain 201 
pumpi[INVESTIGATOR_90359], which independently actuate the  delivery of insulin and glucagon from 202 
cartridges that are separately loaded into the iLet .  The iLet is capable of functioning in an 203 
insulin-only, glucagon-only, or bihormonal configur ation.  The iLet is compatible with three 204 
insulin analog formulations (insulin lispro, Lilly;  insulin aspart and Fiasp, Novo Nordisk) and 205 
one glucagon analog (dasiglucagon, Zealand Pharma).   The iLet also includes a touchscreen 206 
display that enables user interactions through a cu stom graphical user interface with smartphone 207 
simplicity.  Finally, the iLet contains embedded so ftware that includes adaptive control 208 
algorithms that autonomously and continually adapt to the ever-changing insulin requirements of 209 
each individual to enable lifelong adaptive learnin g.  The control algorithms used by [CONTACT_179289] 210 
only require initialization with the user’s body ma ss and are the very same algorithms that were 211 
developed for the [LOCATION_011] University iPhone-Based BP  and were tested and refined in all of the 212 
clinical trials described above (i.e. the Beacon Hi ll Study, the [ADDRESS_320028] Insulin-Only Study, the Bionic 214 
Pancreas Set-Point Study, and the Bionic Pancreas M onitoring Study).  As such, the iLet requires 215 
only the patient’s body weight for initialization.  It does not require carbohydrate counting, nor 216 
does it require any information about the patient’s  total daily dose of insulin, basal or long-acting 217 
insulin requirements, carbohydrate-to-insulin ratio s, or insulin correction factors for managing 218 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 26  OF 97 hyperglycemia.  It is a fully autonomous glycemic c ontrol system that requires very little 219 
management on the part of the patient or provider.  Figure 1 illustrates the iLet’s features and 220 
drug-delivery configurations and is shown together with its compatible CGM devices. 221 
 222 
Figure 1 The commercial version of the iLet bionic pancreas system (Beta Bionics, Inc.) 223 
uses adaptive control algorithms that autonomously and continuously adapt to the patient’s ever- 224 
changing insulin needs to enable lifelong adaptive learning.  The control algorithms in the iLet 225 
only require initialization with the user’s body ma ss, have been tested, refined, and improved 226 
through over 10 years of clinical research.  The iL et can be configured in the insulin-only, 227 
glucagon-only, or bihormonal configurations.  It is  interoperable with one of two CGM devices 228 
and is compatible with three insulin analog formula tions and one glucagon analog.  229 
The iLet is set to either the insulin-only, bihormo nal, or glucagon-only configuration by 230 
manually selecting the desired configuration in the  user interface.  When in the bihormonal 231 
configuration, the control algorithm may occasional ly and automatically invoke the same insulin- 232 
only dosing mode as in the insulin-only configurati on during periods when the glucagon 233 
cartridge has not been loaded, is empty, or becomes  empty during use, or if there is an occlusion 234 
detected in the glucagon fluid path.  Whenever the iLet is in an insulin-only mode, the minimum 235 
glucose target is 110 mg/dl.  Whenever the iLet is in a bihormonal or glucagon-only mode, and 236 
the glucagon fluid path is patent and primed, the m inimum glucose target is 100 mg/dl. [ADDRESS_320029] their 239 
own proprietary connectors to the insulin and gluca gon cartridges in the iLet and to the infusion 240 
site on the patient.   241 
The iLet BP will make recommendations for multiple daily injection (MDI) dosing (for those on 242 
MDI therapy) AND for continuous subcutaneous insuli n infusion (CSII) dosing via an insulin 243 
pump (for those on CSII therapy).  We have shown in  our previous outpatient and home-use 244 

 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 27  OF 97 studies in adult and pediatric participants with T1 D that the total daily dose (TDD) of insulin 245 
used by [CONTACT_263223].  The iLet has three insulin controllers running in 246 
parallel: a basal insulin controller, which continu ally adapts to each individual’s basal metabolic 247 
need for insulin, an MPC controller, which provides  control doses that are required above and 248 
beyond basal insulin, and a meal-announcement contr oller, which continually adapts to the 249 
individual's prandial insulin needs.  The iLet prov ides a daily readout with updated estimates of 250 
daily basal insulin (in terms of a daily long-actin g insulin dose for MDI users and a 24-hour, 251 
four-segment basal rate dose for CSII users), prand ial insulin (for breakfast, lunch, and dinner) 252 
and correction doses.  Thus, the iLet is designed t o provide an up-to-date recommendation of 253 
these quantities for both MDI and CSII users if, fo r any reason, the iLet may be temporarily 254 
unavailable to the user. 255 
Studies conducted using the iLet are summarized in the table below and described in Appendix 256 
A. 257 
Table 4. iLet BP System Studies 258 
 Year Name [CONTACT_263258] N Duration 
of use BP 
Configuration Monitoring Protocol 
Description 
1 2018 Adult 
Bridging 
Study Outpatient, 
unsupervised 
at home, 
2 centers 34 2 arms, 
7 days each Insulin-only Remote 
telemetric 
monitoring Adults aged 18 
and older, 
compared with 
usual care. One 
arm used insulin 
aspart/lispro, the 
other arm used 
Fiasp. 
MGH used 
Senseonics 
Eversense CGM, 
Stanford used 
Dexcom G5 
CGM 
[ADDRESS_320030] time 
5 2019 MultiPK 
BP Study Outpatient, 
unsupervised 
at home Ongoing 3 arms, 
7 days each Insulin-only Remote 
telemetric 
monitoring Adults aged 18 
and older, 
randomized to 
compare one 
week each on 
insulin lispro, 
insulin aspart and 
BioChaperone 
lispro 
1.3.3  Fiasp (Novo Nordisk) 259 
Faster insulin aspart or Fiasp is a formulation of insulin aspart (sold as Fiasp in both the United 260 
States and in Europe) that contains nicotinamide (a lso known as niacinamide or vitamin B3) and 261 
L-arginine hydrochloride (an amino acid).  The addi tion of nicotinamide is intended to result in a 262 
faster initial absorption of insulin aspart followi ng SC injection or infusion.  The addition of L- 263 
arginine hydrochloride stabilizes the Fiasp formula tion.  The active substance (i.e. insulin aspart) 264 
in Fiasp and Novolog is identical and therefore, on ce systemically absorbed, it has the same 265 
biological action at the insulin receptor as that o f Novolog.  Since one of the important 266 
limitations of automated closed-loop glucose contro l is the delay in absorption of insulin, the use 267 
of Fiasp with the bionic pancreas in some individua ls may provide improved glycemic control 268 
relative to lispro or aspart. 269 
1.4  Potential Risks and Benefits of the Investigational  Device and Study 270 
Participation 271 
Risks and benefits are detailed below. Loss of conf identiality is a potential risk; however, data 272 
are handled to minimize this risk.  Hypoglycemia, h yperglycemia and ketone formation are 273 
always a risk in participants with type 1 diabetes and participants will be monitored for this. 274 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 29  OF 97 1.4.1  Known Potential Risks 275 
[IP_ADDRESS]  Venipuncture Risks 276 
A hollow needle/plastic tube may be placed in the a rm for taking blood samples. Blood draws 277 
can cause some common reactions like pain, bruising , or redness at the sampling site.  Less 278 
common reactions include bleeding from the sampling  site, formation of a small blood clot or 279 
swelling of the vein and surrounding tissues, and f ainting. 280 
[IP_ADDRESS]  Fingerstick Risks [ADDRESS_320031] for several weeks.  285 
The risk of local infection is less than 1 in 1000.   This should not be a significant contributor to 286 
risks in this study as fingersticks are part of the  usual care for people with diabetes. 287 
[IP_ADDRESS]  Subcutaneous Catheter Risks (CGM) 288 
Participants using the CGM will be at low risk for developi[INVESTIGATOR_007] a local skin infection at the site 289 
of the sensor needle placement.  If a catheter is l eft under the skin for more than 24 hours it is 290 
possible to get an infection where it goes into the  skin, with swelling, redness and pain.  291 
There may be bleeding where the catheter is put in and bleeding under the skin causes a bruise 292 
(1 in 10 risk). [ADDRESS_320032] a small portion of the sensor under the skin that may cause redness, swelling or pain at the 295 
insertion site.  The participant should be further instructed to notify the study coordinator 296 
immediately if this occurs. 297 
[IP_ADDRESS]  Risk of Hypoglycemia 298 
As with any person having type 1 diabetes and using  insulin, there is always a risk of having a 299 
low blood sugar (hypoglycemia).  The frequency of h ypoglycemia should be no more and [ADDRESS_320033] as at home, there is the possibility of fainting or  302 
seizures (convulsions) and that for a few days the participant may not be as aware of symptoms 303 
of hypoglycemia.  A CGM functioning poorly and sign ificantly over-reading glucose values 304 
could lead to inappropriate insulin delivery. 305 
[IP_ADDRESS]  Risk of Hyperglycemia 306 
Hyperglycemia and ketonemia could occur if insulin delivery is attenuated or suspended for an 307 
extended period or if the pump or infusion set is n ot working properly.  A CGM functioning 308 
poorly and significantly under-reading glucose valu es could lead to inappropriate suspension of 309 
insulin delivery. 310 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 30  OF 97 [IP_ADDRESS]  Questionnaires [ADDRESS_320034] been uncommon. 316 
[IP_ADDRESS]  Other Risks 317 
Some participants may develop skin irritation or al lergic reactions to the adhesives used to secure 318 
the CGM, or to secure the insulin infusion sets for  the continuous subcutaneous insulin infusion.  319 
If these reactions occur, different adhesives or “u nder-tapi[INVESTIGATOR_007]” (such as with IV 3000, Tegaderm, 320 
etc.) will be tried, sites will be rotated frequent ly, and a mild topi[INVESTIGATOR_91101] 321 
medication may be required. 322 
Whenever the skin is broken there is the possibilit y of an infection.  The CGM and pump 323 
infusion sites are inserted under the skin.  It is possible that any part that is inserted under the 324 
skin may cause an infection.  These occur very infr equently, but, if an infection was to occur, 325 
oral and/or topi[INVESTIGATOR_27996].  The r isk of skin problems could be greater if you use 326 
a sensor for longer than it is supposed to be used.   Therefore, participants will be carefully 327 
instructed about proper use of the sensor. 328 
Data downloaded from the CGM, pump, and the home gl ucose and ketone meter will be 329 
collected for the study as measures of diabetes sel f-management behaviors.  Some people may be 330 
uncomfortable with the researchers' having such det ailed information about their daily diabetes 331 
habits. 332 
1.4.2  Known Potential Benefits 333 
One purpose of this research is to reduce the frequ ency of hypoglycemia and severe 334 
hypoglycemic events.  Hypoglycemia is the number on e fear of many individuals and families 335 
with someone who has type 1 diabetes and this fear often prevents optimal glycemic control. 336 
It is expected that this protocol will yield increa sed knowledge about using an automated closed 337 
loop to control the glucose level and is intended t o develop data to support a future PMA 338 
application for approval from the FDA to commercial ly distribute the iLet bionic pancreas in the 339 
[LOCATION_002].  The individual participant may not benefit from study participation. 340 
1.4.3  Risk Assessment 341 
Based on the facts that (1) adults and adolescents with diabetes experience mild hypoglycemia 342 
and hyperglycemia frequently as a consequence of th e disease and its management, (2) the study 343 
intervention involves periodic automated insulin do sing that may increase the likelihood of 344 
hypoglycemia, and periodic automated attenuation of  insulin delivery that may increase the 345 
likelihood of hyperglycemia, (3) mitigations are in  place, and have been tested in prior studies 346 
using the investigational device system in the home  setting, that limit the likelihood of excessive 347 
insulin dosing or prolonged withdrawal of insulin, and (4) rapid reversal of hypoglycemia and [ADDRESS_320035] the ir origin in the Declaration of Helsinki, with 355 
the protocol described herein, and with the standar ds of Good Clinical Practice (GCP). [ADDRESS_320036] the 360 
study. 361 
 362 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 32  OF 97 Chapter 2:  Participation Enrollment and Study Initiation 363 
2.1  Participant Recruitment 364 
Study participants will be recruited from ~[ADDRESS_320037] is 440 (165 particip ants 6–<18 years and 275 participants ≥18 366 
years) in the 13-week randomized trial  such that a  minimum of [ADDRESS_320038] recruitment targ ets. 369 
The study is expected to be conducted at ~ 8 sites t hat will enroll pediatric participants and ~ 8 370 
sites that will enroll adult participants in the Un ited States, although there may be crossing over 371 
of the age groups of participants that sites enroll .  It is anticipated that each pediatric site will 372 
randomize ~15-20 participants and each adult site w ill randomize ~ 30-35 participants.  The 373 
maximum number of randomized participants at a pedi atric site will be 40 and at an adult site 374 
will be 66; and the maximum number enrolled into sc reening at each site will be 60 and 80, 375 
respectively. 376 
No individuals will be excluded on the basis of gen der or race.  An approximately equal gender 377 
distribution between males and females is anticipat ed.  A study goal will be to include 15% of 378 
participants of minority race/ethnicity in the stud y overall. The percentage of minority 379 
race/ethnicity participants is expected to vary by [CONTACT_3725]. 380 
Individuals generally will be recruited from each s ite’s existing patient population or from a pool [ADDRESS_320039] of the 383 
following: 384 
• Culling of pre-existing databases (held by [CONTACT_127958] t he 16 clinical sites, [LOCATION_011] University, 385 
or Beta Bionics, Inc.) of patients who have express ed interest in the bionic pancreas or [ADDRESS_320040], or via phone and will be  provided information about how to 388 
complete the consent process and demographics surve y; 389 
• IRB-approved press release announcing study and stu dy fact sheet; 390 
• Support groups, patient education classes, and not- for-profit community support groups 391 
(e.g., Children with Diabetes, College Diabetes Net work, etc.); 392 
• IRB-approved paper and digital advertisements, broc hures, postcards, flyers, and/or 393 
newsprint advertisements; 394 
• IRB-approved digital advertisements posted on socia l media sites like LinkedIn, Twitter, 395 
YouTube, Instagram, Facebook, and other public foru ms managed by a clinical trial site 396 
or Beta Bionics, Inc.; 397 
• In-person recruitment and telephone recruitment by [CONTACT_179306]; and 398 
• An IRB-approved website dedicated to clinical trial  recruitment. 399 
All recruitment methods and specific advertising ma terials will be approved by [CONTACT_3443] 400 
and/or local IRB prior to their implementation. 401 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 33  OF 97 Participants may be included who completed a separa te screening protocol which determined 402 
eligibility for this protocol (with eligibility ver ified prior to randomization). 403 
2.2  Informed Consent and Authorization Procedures 404 
Potential eligibility may be assessed as part of a routine-care examination or as part of a separate 405 
IRB-approved screening protocol.  Before completing  any procedures or collecting any data that 406 
are not part of usual care, informed consent will b e provided and the participant’s electronic 407 
signatures will be obtained (and assent from minors  as indicated). 408 
For potential study participants ≥18 years old, the study protocol will be discussed with the 409 
potential study participant by [CONTACT_464].  The po tential study participant will be given the 410 
Informed Consent Form to read.  Potential study par ticipants will be encouraged to discuss the 411 
study with family members and their personal physic ians(s) before deciding whether to 412 
participate in the study. If the study participant decides to participate their electronic signature 413 
will be obtained. 414 
For potential participants under 18 years of age, a  parent/legal guardian (referred to subsequently 415 
as “parent”) will be provided with the Informed Con sent Form to read and will be given the 416 
opportunity to ask questions.  Potential participan ts meeting the IRB’s minimum age of assent 417 
will be given a Child Assent Form to read and discu ss with his/her parents and study personnel.  418 
If the parent and child agree to participate, the m inor will verbally provide their assent, and the 419 
parent/legal guardian’s electronic signature [INVESTIGATOR_1318] b e obtained.  A copy of the consent form will be 420 
provided to the participant and his/her parent and another copy will be added to the participant’s [ADDRESS_320041]. 422 
As part of the informed consent process, each parti cipant will be asked to sign an authorization 423 
for release of personal information.  The investiga tor, or his or her designee, will review the 424 
study-specific information that will be collected a nd to whom that information will be disclosed.  425 
After speaking with the participant, questions will  be answered about the details regarding 426 
authorization. 427 
A participant is considered enrolled when informed consent has been obtained. 428 
The principal investigator [INVESTIGATOR_263204] 429 
process is properly followed and that each study pa rticipant is well informed about the study and 430 
the participant’s responsibilities. [ADDRESS_320042] signed consent and started th e screening process may be permitted to 433 
continue into the trial, if eligible, even if the r andomization goal has been reached.  Participants 434 
who turn 18 during the course of the study will nee d to review the adult Informed Consent Form 435 
and re-consent by [CONTACT_263224]. Participants who turn 7 during the course 436 
of the study will need to review the Child Assent F orm and provide assent verbally that they still 437 
want to participate, the parent/LAR will need to re -consent by [CONTACT_263225] [ADDRESS_320043] ~50% aged 6-<12 years and 50% aged 12- 440 
<[ADDRESS_320044] 33% of the cohort ≥ 50 441 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 34  OF 97 years old.  There also will be approximate goals wi thin each of the 3 age strata (6–<12, 12–<18, 442 
and ≥18 years old) for the following: 443 
Pump/multiple daily injection users: at least 33% o f each 444 
HbA1c: at least 33% < 8.0% and 33% ≥ 8.0%; and no more than 20% with HbA1c <7.0% [ADDRESS_320045] Period at 13 weeks (BP Group) will 447 
be randomly assigned (1:1) to either transition bac k to their usual mode of therapy (MDI or 448 
pump therapy) based on therapeutic guidance from th e iLet BP system or transition back to their [ADDRESS_320046] meet  all of the following inclusion criteria and 456 
none of the exclusion criteria at the time of scree ning (which may occur as part of a separate 457 
screening protocol): [ADDRESS_320047] 1 year  460 
2.  Diabetes managed using the same regimen (either pum p or MDI, with or without CGM) 461 
for ≥ 3 months prior to collection of CGM data (either f rom personal Dexcom G6 device 462 
or blinded G6 device) 463 
3.  Age ≥ [ADDRESS_320048] 4 weeks (according to judgmen t of investigator if meter is not 466 
available). 467 
5.  Willingness not to start any new non-insulin glucos e-lowering agent during the course of 468 
the trial. 469 
6.  For participants <18 years old, living with one or more parent/legal guardian 470 
knowledgeable about emergency procedures for severe  hypoglycemia. 471 
7.  For participants >18 years old who live alone, part icipant has a relative or acquaintance 472 
who lives within 30 minutes of participant and is w illing to be contact[CONTACT_263226] 473 
participant if study staff feel that participant ma y be experiencing a medical emergency 474 
and can’t be reached. 475 
8.  Investigator believes that the participant can safe ly use the iLet and will follow the 476 
protocol 477 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 35  OF 97 The investigator will take into account the partici pant’s HbA1c level, compliance [ADDRESS_320049] be willing to 481 
discontinue use while the iLet BP system is being u sed. 482 
Exclusion 483 
1.  Unable to provide informed consent (e.g. impaired c ognition or judgment). 484 
2.  Unable to safely comply with study procedures and r eporting requirements (e.g. 485 
impairment of vision or dexterity that prevents saf e operation of the bionic pancreas, 486 
impaired memory) 487 
3.  Unable to speak and read English. 488 
• For pediatric participants, both caregivers and par ticipants must be able to 489 
speak and read English. 490 
4.  Plan to change usual diabetes regimen in the next 3  months 491 
• This would include changing from MDI to pump, pump to MDI, change in 492 
insulin automation delivery system, starting a CGM if not previously used, 493 
changes in drug therapy specifically for glucose co ntrol except for changes in 494 
one insulin analog to another.  495 
o Changes in insulin dose, carb ratio, sensitivity fa ctor and basal rate 496 
profile are allowed. 497 
5.  Current use of non-FDA approved closed-loop or hybr id closed-loop insulin delivery 498 
system. 499 
6.  Use of Api[INVESTIGATOR_263201]-study rapid-acting insulin  analog and unwilling to switch to 500 
lispro or aspart for the duration of the study. 501 
7.  Known hemoglobinopathy (sickle cell trait is not an  exclusion). [ADDRESS_320050] ete pancreatectomy. 505 
10.  Electrically powered implants (e.g. cochlear implan ts, neurostimulators) that might be [ADDRESS_320051] be used 508 
in the study. 509 
12.  Current use of SGLT2 inhibitors or a sulfonylurea d rug ( use more than 3 months 510 
prior to enrollment is acceptable ). 511 
• If using GLP1 agonist, pramlintide, or metformin dr ugs must be on a stable 512 
dose for 3 months prior to enrollment (as per inclu sion criterion #8,  must be [ADDRESS_320052]).  515 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 36  OF 97 13.  Pregnant (positive urine hCG), breast feeding, plan  to become pregnant in the next [ADDRESS_320053] will be provided to the participant 518 
and verbal report of the result will be acceptable.    519 
14. For adults >[ADDRESS_320054] recent (must be with in the last 2 years) eGFR <30 520 
ml/min OR currently in renal failure on dialysis  521 
• If no eGFR is available for an adult participant du ring the last [ADDRESS_320055] be obtained to confirm eligibility 523 
15.  Presence of a medical condition or use of a medicat ion that, in the judgment of the 524 
investigator, clinical protocol chair, or medical m onitor, could compromise the results 525 
of the study or the safety of the participant.  Con ditions to be considered by [CONTACT_941] 526 
investigator may include the following: 527 
• Alcohol or drug abuse 528 
• Use of prescription drugs that may dull the sensori um, reduce sensitivity to 529 
symptoms of hypoglycemia, or hinder decision making  during the period of 530 
participation in the study 531 
• Coronary artery disease that is not stable with med ical management, including 532 
unstable angina, angina that prevents moderate exer cise (e.g. climbing a flight 533 
of stairs) despi[INVESTIGATOR_45862], or within th e last 12 months before 534 
screening a history of myocardial infarction, percu taneous coronary 535 
intervention, enzymatic lysis of a presumed coronar y occlusion, or coronary 536 
artery by[CONTACT_15806] 537 
• Congestive heart failure with [LOCATION_001] Heart Associ ation (NYHA) 538 
Functional Classification III or IV 539 
• History of TIA or stroke in the last 12 months 540 
• Untreated or inadequately treated mental illness 541 
• History of eating disorder within the last 2 years,  such as anorexia, bulimia, or 542 
diabulemia or omission of insulin to manipulate wei ght 543 
• History of intentional, inappropriate administratio n of insulin leading to [ADDRESS_320056] of employment who is also directly involved i n conducting the clinical trial (as 548 
a study investigator, coordinator, etc.); or having  a first-degree relative who is 549 
directly involved in conducting the clinical trial.   550 
2.4  Eligibility Assessment and Baseline Data Collection  551 
Potential participants will be evaluated for study eligibility through the elicitation of a medical 552 
history and local laboratory testing as needed in t he judgment of the investigator (as part of usual 553 
care). 554 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 37  OF 97 In the event that in-person visits cannot be conduc ted due to institutional restrictions or the 555 
participant’s unwillingness to attend an in-person clinic visit, visits may be conducted virtually 556 
using video conference. Study staff will discuss th e feasibility of conducting video visits with 557 
each participant and provide support as needed to e nsure adequate access.  558 
2.5  Historical Information  559 
A history will be elicited from the participant and /or parent/guardian where applicable and [ADDRESS_320057] to the participant’s diabetes history, [ADDRESS_320058] and current 562 
medications, and drug allergies.   563 
2.6  Screening Testing and Procedures 564 
At the Screening Visit the following procedures wil l be performed: 565 
Informed consent/assent process 566 
Assessment of eligibility 567 
HbA1c assessment via fingerstick or blood draw and measured at local laboratory or 568 
using DCA2000 or equivalent NGSP-certified point-of -care method or (value within 28 569 
days prior to enrollment acceptable) [ADDRESS_320059] will be acceptable. 572 
o If the participant was part of the separate screeni ng protocol, the local HbA1c will 573 
not be collected if the visit is conducted in clini c. 574 
Measurement of height/weight  575 
o If the visit is conducted virtually, a verbal repor t of the participant’s weight and [ADDRESS_320060] will be provided and verbal 581 
report of the result will be acceptable.  582 
Completion of the Clarke Hypoglycemia Awareness Sur vey 583 
Completion of baseline questionnaires (see chapter 8) 584 
For participants who completed the separate screeni ng protocol, eligibility will be reassessed at 585 
the randomization visit.  Participants will not nee d to repeat the point of care/local HbA1c, [ADDRESS_320061]  85% of sensor values in the prior [ADDRESS_320062] be completed prior to randomization.  591 
Users of a personal Dexcom G6 can continue to use t heir personal sensor.  Users of a personal 592 
Dexcom G5 will be provided with an unblinded Dexcom  G6 for baseline data collection. All 593 
others will use a blinded Dexcom G6 sensor that wil l be placed by [CONTACT_2299] (or 594 
parent/guardian) under the supervision of study sta ff.  Participants will be instructed on use and 595 
care of the sensor and on placing a new sensor afte r 10 days (or sooner if necessary). The 596 
supplies may be shipped to the participant and a vi rtual visit completed to monitor sensor 597 
insertion and device startup along with training on  use of the device. 598 
2.8  Screen Failures 599 
Individuals who do not initially meet study eligibi lity requirements may be rescreened at a later 600 
date per investigator discretion. 601 
 602 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 39  OF 97 Chapter 3:  RCT Randomization Visit and Start Up [ADDRESS_320063] randomization visit will be scheduled to oc cur 14–[ADDRESS_320064] baseline CGM data and  who did not participate in the separate 606 
screening protocol .  Participants not in the separ ate screening protocol who meet criteria to skip 607 
the baseline CGM data collection can complete the r andomization visit on the same day of the 608 
screening visit or any time within 21 days followin g the screening visit. 609 
3.2  Testing and Procedures 610 
The following will be done at the randomization vis it: [ADDRESS_320065] 85% of CGM values during 14 days of CGM wear (unless CGM run-in was 613 
skipped) [ADDRESS_320066] study visit (if not on the same da y as the screening visit) 617 
Verify eligibility if randomization visit is not on  the same day as the screening visit 618 
Verify that participant understands the protocol an d is willing to accept assignment to any 619 
treatment group 620 
Measure height and body weight (if not within 7 day s of screening visit).  621 
o If the visit is conducted virtually, a verbal repor t of the participant’s weight and [ADDRESS_320067]-menarche and premenopausal women who are 625 
not surgically sterile (can be skipped if Randomiza tion Visit occurs within 7 days of the 626 
Screening Visit) [ADDRESS_320068] blood sample for storage.   633 
o Blood drawn may include serum and plasma; participa nts will have the option of 634 
declining. 635 
o If the participant consents to having blood samples  stored, but the visit is conducted 636 
virtually, the samples may be collected at a later in-clinic visit for the study.  637 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 40  OF 97 3.3  Randomization 638 
Pediatric participants (6–<18 years old) for whom e ligibility has been verified will be randomly 639 
assigned in a 2:1 ratio to:  640 
Insulin-only Bionic Pancreas (BP) Group with lispro  or aspart  641 
Control Group 642 
Adult participants ( ≥18 years old) for whom eligibility has been verifie d will be randomly 643 
assigned in a 2:2:1 ratio to  644 
Insulin-only Bionic Pancreas (BP) Group with lispro  or aspart  645 
Insulin-only Bionic Pancreas (BP) Group with Fiasp 646 
Control Group 647 
The participant’s randomization group assignment is  determined by [CONTACT_3446] [ADDRESS_320069] using a block design separately for each cente r. 650 
Note: randomization will not be stratified by [CONTACT_654], HbA1c or other factors because of the small 651 
number per site that is possible and considering th e 2:2:1 randomization in adults and 2:1 652 
randomization in pediatrics.  If an imbalance in ag e or baseline HbA1c exists among groups, 653 
an adjustment will be made in the analytic model. 654 
3.4  Study Procedures for the Control Group 655 
Participants in the Control Group will be instructe d to follow their usual diabetes management as 656 
directed by [CONTACT_263227] (see secti on 4.2). For users of the Dexcom G6, they will [ADDRESS_320070] phase. 661 
3.5  Study Procedures for the BP Group 662 
Initiation of BP use for the BP Group will occur on  the day of randomization. If the visit is 663 
conducted virtually, initiation of the BP may be de layed until the device and supplies are 664 
provided to the participant (via shippi[INVESTIGATOR_263205] o ff/pi[INVESTIGATOR_9107]) and training is provided. The 665 
training may be done in person or via a Zoom, Skype , or similar video conference. 666 
 667 
The approach to training of the BP Group will depen d on whether the participant is already a 668 
pump and/or CGM user.  The training on use of the B P may occur completely at this visit or may [ADDRESS_320071] the iLet BP device. 672 
Study staff will review the use of the study device s including the iLet BP, blood glucose 673 
meter, and ketone meter, and the study CGM system. 674 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 41  OF 97 Participants will be trained to only use only finge rsticks when measuring blood glucose 675 
levels with the blood glucose meter. Alternate site  testing will not be used. 676 
Participants will be trained on the use and mainten ance of the Dexcom G6 CGM. 677 
o Participants will be trained on sensor insertion an d optional calibration procedures.  678 
They will insert their own sensor using an approved  insertion site and study staff will 679 
confirm they are doing it properly.  680 
o All participants will be trained on possible CGM er rors and how to respond promptly 681 
to resume closed loop control by [CONTACT_263228]. 682 
The control algorithm will be initialized with the participant’s current weight. [ADDRESS_320072] cases, but 684 
may be set to the “high” target in participants on MDI and using long-acting insulin at [ADDRESS_320073] a high 686 
A1c and may experience hypoglycemic symptoms in the  normal plasma glucose range. 687 
The iLet BP will be configured to recognize the Dex com G6 CGM signal and will be 688 
paired with the participant’s transmitter. 689 
Study staff will supervise the participant preparin g the insulin cartridge, loading the 690 
cartridge into the iLet and inserting the infusion set. 691 
The participant will remove his/her own insulin inf usion pump (if used) and the 692 
participant will start the bionic pancreas. 693 
The staff will confirm that the iLet BP is function ing properly prior to discharging the 694 
participant. 695 
Study staff will provide supplies for use with the study CGM, study glucose and ketone 696 
meters and the iLet. 697 
Due the adaptive nature of the BP, participants on multiple daily injections may simply be started 698 
on the BP without a need for active management of t he transition period by [CONTACT_464], but the 699 
new equilibrium will not be reached until all of th e long-acting insulin glargine has completely 700 
cleared their system, which may take 48 hours or mo re.  In participants using a long-acting 701 
insulin pre-study, the glucose target may be set to  the “high” setting for the 3 or more days 702 
before moving down to the default target.  Particip ants will be trained that they may see 703 
escalating dosing by [CONTACT_263229]. 704 
 705 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 42  OF 97 Chapter 4:  RCT Outpatient Study Procedures 706 
4.1  Outpatient Procedures for Both Groups 707 
Participants will be advised not to use alcohol or other drugs in sufficient quantity to reduce 708 
sensitivity to symptoms of hypoglycemia or hinder a ppropriate decision-making. 709 
Any medical advice needed by [CONTACT_263230] g their participation that is not directly 710 
related to the study protocol should be obtained in  the usual manner with their own physician. 711 
There are no restrictions of any kind on diet, exer cise, or other activities. 712 
Participants will be asked to complete a once-weekl y survey including questions about 713 
hypoglycemia and carbohydrate interventions that oc curred in the prior 24 hours. 714 
• With participant permission, text and/or email will  be sent at the time when survey [ADDRESS_320074] the ability to complete the 732 
questionnaires electronically, paper questionnaires  may be provided. Participants will be 733 
reminded that their eligibility for the separate Ex tension Study (Control Group) is dependent on [ADDRESS_320075] 735 
80% of the expected CGM data during the 13-week RCT , and on completion of all study visits. 736 
4.2  Outpatient Procedures for Control Group 737 
The Control Group will continue its pre-study diabe tes management, including approach to 738 
insulin delivery.  Diabetes management will be hand led by [CONTACT_2299]’s diabetes health care [ADDRESS_320076] period. Training and su pplies for the Dexcom G6 supplies will be 748 
provided to these participants as needed.   749 
• Participants will be trained on the insertion of th e sensor at an approved sensor insertion 750 
site and use of the Dexcom G6 CGM.  They will inser t their own sensor and study staff 751 
will confirm they are doing it properly.  Participa nts will be instructed to only use 752 
approved insertion sites (abdomen for adults and ab domen or upper buttocks for 753 
participants 6-<18), and to insert a new sensor eve ry 10 days or sooner if the sensor 754 
comes off prior to day 10 of CGM wear.  755 
 756 
4.3  Outpatient Procedures for BP Group 757 
Participants using the iLet will not be allowed to travel outside the [LOCATION_002] or its territories  758 
for the entire time the system is in use.   759 
Participants may perform calibrations of the Dexcom  G6 CGM if it is inaccurate relative to a BG 760 
measurement, per the device manufacturer’s instruct ions. [ADDRESS_320077]- acting carbohydrates and a glucagon emergency 762 
kit easily accessible in case they are needed. 763 
Following the initiation of use of the iLet, partic ipants with hypoglycemia unawareness (Clarke 764 
Hypoglycemia Awareness Survey score >=4) will be as ked to perform an overnight fingerstick 765 
blood glucose measurement (between 2-3AM) for 2-3 n ights. They will be trained that if SMBG 766 
is <70 mg/dL they should treat with carbohydrate, w ith less carbohydrate (e.g. 5 g) as the initial 767 
treatment if the SMBG is >60 mg/dL or if the CGM tr end is not sharply downward, and more [ADDRESS_320078] (up to 15 769 
g), recheck in [ADDRESS_320079] appropriate for 774 
each individual.  775 
Study staff will recommend a low CGM glucose alarm be set for 70 mg/dl or lower and a high 776 
CGM glucose alarm be set for 250 mg/dl or higher. [ADDRESS_320080] suspended insulin 783 
delivery prior to the occurrence of hypoglycemia. T hey will be trained to continue to monitor 784 
their glucose levels until they return to normoglyc emia. 785 
If the glucometer confirms hyperglycemia, participa nts will be trained to assess their infusion set 786 
and tubing for patency, the insulin reservoir for s ufficient insulin supply, the iLet BP for 787 
sufficient battery power, proper functioning, and i nsulin delivery. If hyperglycemia > 300 mg/dl 788 
persists for more than 90 minutes they will be trai ned to check their blood ketone level using the 789 
Precision Xtra blood ketone meter. 790 
• If ketones are ≥0.6 mmol/l, they will be trained to replace their i nfusion set and to 791 
inform study staff.  They will be trained to contin ue to monitor their glucose and 792 
blood ketone levels until they return to normoglyce mia and ketones are < 0.6 793 
mmol/l. 794 
• If ketones are <0.6 mmol/l, they will be advised to  continue to monitor their glucose 795 
until it returns to normoglycemia and to repeat the  ketone measurement in 90 796 
minutes if necessary 797 
If the glucometer reading is not consistent with th e CGM glucose reading, participants will be 798 
trained to look for possible scenarios that could l ead to an inaccurate CGM reading.  799 
• They will be educated about the lag between interst itial and capi[INVESTIGATOR_162669] [ADDRESS_320081] difference betwe en CGM and capi[INVESTIGATOR_162669] 802 
readings, and to consider the CGM inaccurate if it is >20% different than their 803 
capi[INVESTIGATOR_179274]. If their CGM glucose is not changing rapi[INVESTIGATOR_179273] >20% 804 
different from their capi[INVESTIGATOR_179274], the y will be instructed to calibrate 805 
their CGM if possible. 806 
• A compression artifact at the site of the sensor ma y cause false hypoglycemic [ADDRESS_320082] with troubleshooting.  813 
This meeting may be delayed until morning if the pr oblem occurs overnight —in this 814 
case, the participant will use their own pump or us e injectable insulin until a meeting is 815 
possible.  A member of the study staff (within thei r scope of practice and under the 816 
supervision of the site principal investigator) may  advise them on how to manage their 817 
diabetes in the interim.  If necessary, the BP devi ce may be replaced. 818 
• If there is a complete failure of the iLet BP opera tion and it is anticipated that [ADDRESS_320083] always be within 12 hours. 823 
• If the CGM sensor is not reading glucose levels, th e system will provide basal insulin [ADDRESS_320084] a BG measurement every 2 hours wh en the CGM signal is not 828 
available, but the system will remain in closed-loo p mode even if CGM data are not 829 
available. Participants will be trained in various ways to bring their study CGM sensor 830 
back online. This may involve replacement of the De xcom G6 CGM sensor. Normal 831 
(online) BP control will resume automatically when the CGM sensor is reporting 832 
glucose values again. 833 
• Study staff will contact [CONTACT_263231] l troubleshooting as necessary. [ADDRESS_320085] of choosing the size  of the meal relative to typi[INVESTIGATOR_263206] 836 
participant (more, usual for me, less, much less). Participants will be trained not to announce 837 
snacks that occur between major meals.  838 
Participants will be trained on the interface to ch ange the glucose targets.  They will be asked to 839 
consult with study staff before making any changes to the permanent target or to setting a 840 
daily/night recurring target alteration schedule.  841 
Participants will be asked to change their infusion  set every 3 days or sooner if there is a 842 
problem. 843 
Participants will be instructed to change the insul in cartridges, cap connectors, and tubing 844 
whenever one of two conditions are met: (1) when th ere is <20 units remaining in the cartridge, 845 
or (2) the cartridge or tubing have been in place f or the maximum number of days according to 846 
the labeling for the insulin being used. 847 
A new Dexcom CGM sensor will be placed in an approv ed sensor insertion site every 10 days 848 
for Dexcom users if no replacement was required bef ore this time.  The iLet BP will generate an 849 
alarm when replacement is required. 850 
Participants will be asked to charge their iLet BP routinely (preferably at least once daily, such 851 
as when they are bathing) and whenever they notice the battery level is low.  The iLet BP will [ADDRESS_320086]. 854 
The iLet BP is water resistant but participants wil l be instructed to remove it for showering and 855 
swimming and to keep it dry during exercise. 856 
Participants will be trained to take appropriate pr ecautions when they are disconnected from the 857 
iLet BP, including frequent BG checks using the stu dy Contour Next One glucometer if they are 858 
not monitoring CGM glucose by [CONTACT_179323] (e.g. their phone) and to have carbohydrate 859 
readily available.  They are urged to limit the amo unt of time they are disconnected from the iLet 860 
BP to ensure optimal glucose control. 861 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 46  OF 97 If a participant develops an illness during the stu dy, he/she can seek medical care as usual. If the 862 
participant is unable to eat for a period exceeding  one day, he/she must notify study staff so that [ADDRESS_320087] the study staff as soon as possible and discontinue iLet 866 
BP System use. 867 
If a participant discontinues use of the BP system either due to investigator judgment that it is 868 
not safe for the participant to continue to use the  iLet in closed loop mode or the participant’s 869 
choice, the participant will  return to his/her pre study insulin delivery and glucose monitoring 870 
method. If the participant is not using a personal G6 sensor, he/she will be asked to wear a 871 
blinded sensor for data collection at the scheduled  time points as described in section 5.2.2. 872 
 873 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 47  OF 97 Chapter 5:  RCT Follow-up Study Visits [ADDRESS_320088] s is the same for all treatment groups. 876 
Phone contacts will occur after 1-2 days and after 7 (± 2) days. 877 
Clinic visits will occur after 2 weeks (± 4 days), and then at 6 weeks (± 4 days), and 10 weeks 878 
(± 4 days) prior to the 13-week primary outcome vis it (window 91-98 days from randomization). 879 
In the event that in-person visits cannot be conduc ted due to institutional restrictions or the 880 
participant’s unwillingness to attend an in-person clinic visit, visits may be conducted virtually [ADDRESS_320089] week of participation. Study 885 
staff will query the participant for any adverse ev ents and assess the participant’s ability to [ADDRESS_320090] a change to the 888 
permanent glucose target if indicated. 889 
5.2.2  Clinic Visits 890 
The following procedures will be performed at each in-clinic visit, unless otherwise specified: [ADDRESS_320091] will be provided to the 895 
participant and verbal report of the result will be  acceptable. 896 
Study staff will measure the participant’s height a nd weight at 6 weeks and 13 weeks.  897 
o If the visit is conducted virtually, a verbal repor t of the participant’s weight and [ADDRESS_320092] a scale at home. 900 
o In the BP Group, if the weight has changed outside of ±15% of its current value, 901 
then the weight will be updated on the iLet GUI wit h the new value.   902 
Study staff will review any changes in the particip ant’s medical history or [ADDRESS_320093] study visit. 905 
For the BP Group, recent CGM data (e.g. on the iLet ’s graph screen and/or in the 906 
summary statistics provided on the mobile app used by [CONTACT_263232] 907 
iLet data in the case of in-clinic study visits) wi ll be reviewed and study staff may [ADDRESS_320094] mid-study visits (e.g. at the 6-week visit o r more often as needed) by [CONTACT_5640] (1) 913 
a study staff member visiting the participant or (2 ) shippi[INVESTIGATOR_007] a study tablet to the 914 
participant and guiding the participant through the  data download process remotely. 915 
For the final 13-week visit, participants who come to clinic will give back their iLet 916 
and participants who are unable to come to clinic w ill factory-reset their iLet (which 917 
will end their 13-week iLet treatment session but w ill not delete the data for the 918 
treatment session from the iLet) and ship the iLet back to the study site. In all cases, a 919 
final full data download will be performed. 920 
At all scheduled visits prior to the 13-week visit,  a CGM sensor will be placed for 921 
participants in the Control Group (unless the parti cipant is already wearing one). A 922 
CGM sensor will be placed for anyone in BP Group wh o has stopped using the iLet 923 
BP system and discontinued CGM but is willing to we ar a Dexcom G6 sensor.  924 
Study staff will provide supplies as needed and wil l go over the study procedures 925 
reminders. 926 
Completion of the Clarke Hypoglycemia Awareness Sur vey at 13 weeks. 927 
At 6 weeks and 13 weeks, blood will be collected fo r central HbA1c. 928 
• At [ADDRESS_320095] th e option of declining. 930 
At 6 weeks and 13 weeks, participants will complete  questionnaires.  931 
Parents/guardians where applicable also may complet e questionnaires. [ADDRESS_320096] 80% of the expected CGM data.  If yes, the pa rticipant will be offered participation in an [ADDRESS_320097] (BP Group) 939 
will enter the Transition Phase and be randomly ass igned (1:1) either to transition back to their [ADDRESS_320098].  See chapter 6 for 942 
details about the Transition Phase procedures and v isit schedule. 943 
Note: randomization will be stratified by [CONTACT_263233], HbA1c or other factors because of 944 
the small number per site.  If an imbalance in age or baseline HbA1c exists among groups, an 945 
adjustment will be made in the analytic model used to analyze the Transition Study outcomes.   946 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 49  OF 97 Chapter 6:  Transition Phase [ADDRESS_320099] will e nter the Transition Phase at the time that BP 949 
use ends (assuming BP use does not stop prematurely  before the intended end of use - in such 950 
cases, therapeutic guidance will be provided by [CONTACT_263234] 951 
participant’s pre-study management). 952 
6.2  Randomization 953 
Participants in the Transition Phase will be random ly assigned (1:1) to either transition back to [ADDRESS_320100] ion factor and/or sliding scale of insulin for 962 
hyperglycemia. 963 
For those participants who use MDI therapy for thei r usual care, the iLet BP will recommend the 964 
daily dose of long acting insulin, the average pran dial insulin dose (e.g. insulin lispro or insulin 965 
aspart) for typi[INVESTIGATOR_263207], middle, an d end periods of the day, and a sliding-scale 966 
correction dose of insulin (e.g. insulin lispro or insulin aspart) for hyperglycemia. [ADDRESS_320101] one follow-up visit after 2-4 days. The visit may be conducted 969 
virtually. A daily survey will be completed about h ypoglycemia events, treatment and deviations 970 
from recommended dosing. 971 
 972 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 50  OF 97 Chapter 7:  Study Drugs and Devices 973 
7.1  Study Drugs 974 
The study involves subcutaneous administration of i nsulin lispro (Humalog, Eli Lilly), insulin 975 
aspart (Novolog, Novo Nordisk), or Fiasp (Novo Nord isk), the latter for adults only.  Lispro, [ADDRESS_320102] diabetes regimen with 979 
the insulin prescribed by [CONTACT_263235] .  Pediatric subjects randomized to the BP 980 
Group will fill the iLet ready-to-fill insulin cart ridge with either lispro or aspart.  Adult subjects  981 
randomized to the BP Aspart/lispro Group will fill the iLet ready-to-fill insulin cartridge with 982 
either lispro or aspart. If a participant was using  Fiasp, he/she will need to switch to either lispro  983 
or aspart for the study.  Adult subjects randomized  to the BP Fiasp Group will be provided with 984 
Fiasp in PumpCart  ® cartridges size 1.6 mL.  Fiasp will be called “Fas ter Aspart” on the cartridge 985 
label. However, it will be clarified to the partici pants in the study informed consent form as well 986 
as verbally and with a handout when Fiasp is dispen sed, that this does not imply that Fiasp is 987 
faster than insulin aspart in the iLet device. 988 
The control system can administer bolus doses of in sulin up to every five minutes.  A single 989 
automated bolus of insulin will not exceed 3 units per 5-minute dose [30 µl] (or 6 units [60 µl] if 990 
it is in response to isolated BG entries when the C GM is offline) and a single meal priming dose, 991 
which is triggered by [CONTACT_28024], will not exceed 24 units [240 µl].  The dual pump can administer 992 
as little as 0.50 µl (0.05 units of U-100 insulin) in a single bolus dose.  Insulin exposure is [ADDRESS_320103] their infusion set as needed when it fails (or is suspected of failing) or falls out, or every  1000 
2–3 days. 1001 
7.2.2  iLet Ready-to-Fill Insulin Cartridges 1002 
Participants in the BP Groups will be provided with  iLet ready-to-fill insulin cartridges for the 1003 
system (these are packaged with a drug-transfer hub  and plunger rod, which are used in the 1004 
process of transferring insulin from a vial to the ready-to-fill insulin cartridge).  Study staff will  [ADDRESS_320104] their ready- 1007 
to-fill insulin cartridge as needed (when it is nea rly empty), when it fails (or is suspected of 1008 
failing), or every 3 days. 1009 
7.2.3  Continuous Glucose Monitors 1010 
Participants using the iLet BP in all phases will u se a Dexcom G6 sensor. 1011 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 51  OF 97 [IP_ADDRESS]  Dexcom G6 CGM 1012 
A transcutaneous glucose sensor for the Dexcom G6 C GM will be inserted in the subcutaneous 1013 
tissue and will provide input to the controller.  O nly approved insertion sites will be used 1014 
(abdomen for adults and abdomen or upper buttocks f or participants 6-<18). The sensor is [ADDRESS_320105]- 1021 
randomization for all participants randomized to th e Control Group. 1022 
7.2.4  iLet Bionic Pancreas  1023 
The iLet BP has an integrated graphical user interf ace (GUI) and touchscreen display that 1024 
displays the current CGM glucose from the Dexom G6 sensor, a graphical history of the CGM 1025 
glucose, and doses of insulin delivered by [CONTACT_263236].  The GUI can also be used to 1026 
input optional meal announcements, designating qual itatively the meal carb content as “More”, 1027 
“Usual for Me”, “Less”, or “Much Less”.  This will trigger a partial meal-priming bolus, the size 1028 
of which will adapt during the course of the trial in accordance with the insulin needs for that 1029 
size and mealtime (e.g. a portion of the mealtime i nsulin need). 1030 
The target BG for the BP is 120 mg/dl by [CONTACT_15094] (“ Usual”), but the user may designate a lower 1031 
default target (of 110 mg/dl, “Lower”) or a higher default target (of 130 mg/dl, “Higher”). 1032 
A higher or lower default target can be set indefin itely, or for a limited time with automatic 1033 
expi[INVESTIGATOR_1516], or for a recurring limited time with au tomatic renewal and expi[INVESTIGATOR_1516].  When a 1034 
temporary target is set, upon expi[INVESTIGATOR_263208] 1035 
target.  Although previous studies showed that the BP decreased hypoglycemia and the need for 1036 
carbohydrate interventions relative to usual care, this will allow participants to raise the BG 1037 
target for additional safety during periods when hy poglycemia would be particularly 1038 
problematic, such as when driving or otherwise unab le to check or attend to their BG for a period 1039 
of time, or during periods when hypoglycemia is mor e likely, such as during exercise.  It may 1040 
also be used to raise the mean BG if the average is  unnecessarily low and the user prefers to 1041 
further reduce the risk of hypoglycemia.  The use o f this feature will be entirely optional—it will [ADDRESS_320106] the 1054 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 52  OF 97 administration of insulin basal rates either based on the participant's weight in the first 24 hours 1055 
of the experiment, or on the average of adaptively determined basal rates for that time of day 1056 
once sufficient experience has been accumulated (i. e. 24 hours or more) by [CONTACT_179311]. [ADDRESS_320107] tested the accuracy of this mete r and found it to be highly accurate and 1067 
reliable BG measurements will be obtained via finge rstick with this meter in the BP Groups. 1068 
7.2.6  Precision Xtra Blood Ketone Meter 1069 
The Precision Xtra blood ketone meter is an FDA app roved ketone meter that is commercially 1070 
available.  Blood ketone measurements during epi[INVESTIGATOR_263209] 1071 
fingerstick with this meter in the BP Groups. 1072 
7.3  Participant Access to Study Device at Study Closure  1073 
Participants will be permitted to keep the blood gl ucometer and blood ketone meter at the end of 1074 
the study, but will need to return all other device s. 1075 
 1076 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 53  OF 97 Chapter 8:  Laboratory Testing, Questionnaires and Focus Group 1077 
8.1  Laboratory Testing 1078 
HbA1c:  1079 
Performed locally at the Screening visit. This may be skipped if the visit is conducted 1080 
virtually. 1081 
Collected for central lab analysis on a schedule as  indicated in the visit grids for each 1082 
phase. 1083 
C-peptide and Glucose: 1084 
• Collected for central lab analysis at the RCT rando mization visit. 1085 
o If the visit is conducted virtually, this will not be completed. 1086 
 1087 
Urine Pregnancy:  [ADDRESS_320108], questionnaires will be completed at the 6- week and 13-week visit (or within 1 week 1096 
leading up to each timepoint).  In addition, there will be a customized questionnaire completed at 1097 
the end of the Transition Phase that will query the  participant about how they handled the 1098 
transition and satisfaction with the iLet recommend ations. 1099 
Each questionnaire is described briefly below.  The  procedures for administration will be 1100 
described in the study procedures manual.  Age-appr opriate versions of each questionnaire will 1101 
be administered wherever possible.  Parents/guardia ns of pediatric participants may complete 1102 
parent versions of these questionnaires where appli cable. It is estimated that questionnaires will 1103 
take less than 1 hour to complete for participants and parents of participants <18 years of age. 1104 
8.2.2  Brief Description of Questionnaires 1105 
 1106 
Table 5. Psychosocial Questionnaires for the Person  With Diabetes (PWD) [ADDRESS_320109] Measured / Relevant 
Points Who 
Completes/Age 
Range Timing of 
Administration in 
RCT 
Diabetes-Specific 
Emotional Distress 
. DDS for Adults 
. PAID-C for 8-12 yrs 
. PAID-T for 13-<[ADDRESS_320110] measures for 
understanding distress symptoms 
related to diabetes.  
.DDS = 28 items  
.PAID-C = 11 items  • DDS: >18 
• PAID-C: 8-
12 
• PAID-T: 13-
<18  Baseline, 6 weeks and 
13 weeks 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 54  OF 97 .PAID -T = 14 items  
Hypoglycemia 
Confidence Includes 8 different common 
situations where hypoglycemia occurs 
(e.g., physical activity, driving) and 
evaluates level of confidence in those 
situations ( 9 items)  >18 through 
adults Baseline, 6 weeks and 
13 weeks 
Diabetes Technology 
Attitudes Subjective questions about attitudes 
related to diabetes technologies and 
devices (5 items)  >18 through 
adults Baseline, 6 weeks and 
13 weeks 
INSPI[INVESTIGATOR_263210] 
• Adult Pre/Post  
• Youth Pre/Post 
 Measures psychological expectations 
and response to closed loop treatment.  
Adult  survey has 22 items 
Youth  version 17 items.  
 Adult: >18 
Youth: 8- <[ADDRESS_320111] surveys 
will occur at 13 weeks  
Fear of Hypoglycemia 
Scale 
 
• Adult Scale  
• Youth Scale The HFS measures several dimensions 
of fear of hypoglycemia among adults 
with type 1 diabetes.  
• Adults:  Worry (18 items) and 
behavior (15 items)  
• Youth:   Worry (15 items) and 
behavior (10 items)  
 Adult: >18 
Youth: 8- <18 Baseline, 6 weeks and 
13 weeks 
Diabetes Treatment 
Satisfaction 
Questionnaire 
• . Baseline version 
(s) 
• .Change version (c)  The DTSQ measures patient 
satisfaction with diabetes treatment 
and perceived frequency of 
hyperglycemia and hypoglycemia. 
Adult version (s and c) 8 items 
Teen version (s and c) 12 items 
 Adult:  >18 
 
Youth (Teens): 
13-17 
 
 Baseline (s) version at 
the baseline and at 13 
weeks for all 
 
Change (c )version at 
13 weeks for all  
EQ5D (5L and Y 
versions) NICE approved QOL measure that 
translates into economics  
5 items  
 Y version: 
 
5L Version: >18 
Y Version: 8-
<18  Baseline, 6 weeks and 
13 weeks 
WHO-5 5 items  >8 through 
adults  Baseline, 6 weeks and 
13 weeks  
Bionic Pancreas User 
Opi[INVESTIGATOR_179267] 35 items  >[ADDRESS_320112] Experience with 
Artificial Pancreas 
Systems 9 items >8 through 
adults ONLY administered at 
13 weeks, and ONLY 
to those who are using 
the BP. NOT to the 
Control  Group  
 1108 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 55  OF 97 Table 6. Psychosocial Questionnaires for Parents of  Children Ages 6- <[ADDRESS_320113] Measured / Relevant 
Points Age Range Timing of 
Administration in 
RCT 
Diabetes-Specific 
Emotional Distress 
. P-PAID-C for 8-12 
yrs 
. P-PAID-T for 13-<[ADDRESS_320114] measures for 
understanding distress symptoms 
related to diabetes.  
.P-PAID-C = 16 items 
.P-PAID-T = 15 items P-PAID-C: 
Parents of those 
ages 6-12 
P-PAID-T: 
Parents of those 
ages 13 -<18  Baseline, 6 weeks and 
13 weeks 
INSPI[INVESTIGATOR_263211]/Post  
 Measures psychological expectations 
and response to closed loop treatment.  
Parent pre and post measures  
21 items 
 Parents of youth 
ages 6-<[ADDRESS_320115]-Inspi[INVESTIGATOR_263212] 13 weeks  
Fear of Hypoglycemia 
Scale 
• Parent report 
scale 
 The HFS measures several dimensions 
of fear of hypoglycemia among 
parents of youth with type 1 diabetes.  
. Parent: Worry (15 items) and 
behavior (11 items)  
 Parents of youth 
ages 6-<18 Baseline, 6 weeks and 
13 weeks 
Diabetes Treatment 
Satisfaction 
Questionnaire 
• Baseline 
version 
• Change 
version  The DTSQ measures patient 
satisfaction with diabetes treatment 
and perceived frequency of 
hyperglycemia and hypoglycemia. 
Parent version (s and c) 14  items 
 
 Parents of youth 
ages 6-<18 Baseline (s) version at 
the baseline and at 13 
weeks for all 
 
Change (c )version at 
13 weeks for all 
Bionic Pancreas User 
Opi[INVESTIGATOR_179267] 35 items  Parents of youth 
ages 6-<[ADDRESS_320116] Experience with 
Artificial Pancreas 
Systems 9 items Parents of youth 
ages 6-<18 ONLY administered at 
13 weeks, and ONLY 
to those who are using 
the BP. NOT to the 
Control  Group  
 1110 
8.3  Focus Groups 1111 
Focus Groups 1112 
Focus groups will be completed for participants ass igned to the BP Group who agree to 1113 
participate. Focus groups (or individual interviews , depending on participants’ schedules) will [ADDRESS_320117] completed th e BP Group (this is 14-[ADDRESS_320118] study 1115 
start).  Virtual focus groups will be conducted usi ng HIPAA-approved software supported by 1116 
Northwestern University and run by [CONTACT_263237] L urie Children’s Hospi[INVESTIGATOR_307], Department of 1117 
Pediatrics of Northwestern University’s Feinberg Sc hool of Medicine. Focus groups will be run 1118 
with 3-6 participants who are in the same developme ntal age group (e.g. children, adolescents, 1119 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 56  OF 97 young adults, adults, parents) and a script of open -ended questions will be used to gather [ADDRESS_320119] o f wearing the iLet BP system. There will also 1121 
be time for discussion of content raised by [CONTACT_263238]. Use of a moderator with advanced 1122 
training will help ensure consistency across groups . Trained study coordinators will observe the 1123 
focus groups and take field notes. The study coordi nator will keep time and manage group 1124 
logistics. Sessions will be audio- and video-taped and transcribed by a professional transcription 1125 
service. 1126 
  1127 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 57  OF 97 Chapter 9:  Unanticipated Problems, Adverse Events, and 1128 
Device Issue Reporting 1129 
9.1  Unanticipated Problems 1130 
Site investigators will promptly report to the Coor dinating Center on an eCRF all unanticipated 1131 
problems meeting the criteria below.  Problems meet ing IRB reporting requirements will be 1132 
reported to the IRB within 7 calendar days of the s ite becoming aware of the problem.   For this 1133 
protocol, an unanticipated problem is an incident, experience, or outcome that meets all of the 1134 
following criteria: 1135 
Unexpected (in terms of nature, severity, or freque ncy) given (a) the research procedures 1136 
that are described in the protocol related document s, such as the IRB-approved research 1137 
protocol and informed consent document; and (b) the  characteristics of the subject 1138 
population being studied 1139 
Related or possibly related to participation in the  research (possibly related means there is [ADDRESS_320120] been caused 1141 
by [CONTACT_3459]) 1142 
Suggests that the research places participants or o thers at a greater risk of harm than was 1143 
previously known or recognized (including physical,  psychological, economic, or social 1144 
harm) 1145 
The Coordinating Center also will report to the IRB  all unanticipated problems meeting reporting 1146 
requirements, within 7 calendar days of becoming aw are of the problem, that are not directly 1147 
involving a specific site, such as unanticipated pr oblems that occur at the Coordinating Center or 1148 
at another participating entity such as the central  laboratory. 1149 
9.2  Adverse Events 1150 
9.2.1  Definitions 1151 
Adverse Event (AE): Any untoward medical occurrence  in a study participant, irrespective of the 1152 
relationship between the adverse event and the devi ce(s) under investigation. 1153 
Serious Adverse Event (SAE): Any untoward medical o ccurrence that: 1154 
Results in death. 1155 
Is life-threatening; (a non-life-threatening event which, had it been more severe, might [ADDRESS_320121] become life-threatening, is not necessarily co nsidered a serious adverse event). 1157 
Requires inpatient hospi[INVESTIGATOR_1081]. 1158 
Results in persistent or significant disability/inc apacity or substantial disruption of the [ADDRESS_320122] normal life functions (sight thr eatening). [ADDRESS_320123]. 1161 
Is considered a significant medical event by [CONTACT_263239] 1162 
(e.g., may jeopardize the participant or may requir e medical/surgical intervention to 1163 
prevent one of the outcomes listed above). [ADDRESS_320124] (UADE): Any ser ious adverse effect on health or safety or [ADDRESS_320125], 1166 
problem, or death was not previously identified in nature, severity, or degree of incidence in the 1167 
investigational plan or application (including a su pplementary plan or application), or any other 1168 
unanticipated serious problem associated with a dev ice that relates to the rights, safety, or 1169 
welfare of participants (21 CFR 812.3(s)). [ADDRESS_320126] (ADE): Any untoward medical o ccurrence in a study participant which a [ADDRESS_320127] contributed (note that an Adverse 1172 
Event Form is to be completed in addition to a Devi ce Deficiency or Issue Form, unless excluded 1173 
from reporting as defined in section 9.2). An event that occurs solely due to participant (i.e ., 1174 
user) error in which the device functions properly generally will not be considered an ADE 1175 
unless it is determined that the instructions on th e screen of the device or user manual (or 1176 
similar training materials) may have contributed to  the event (note: the event may still meet 1177 
criteria for reporting as an adverse event).  1178 
Device Complaints and Malfunctions: A device compli cation or complaint is something that 1179 
happens to a device or related to device performanc e, whereas an adverse event happens to a 1180 
participant.  A device complaint may occur independ ently from an AE, or along with an AE.  1181 
An AE may occur without a device complaint or there  may be an AE related to a device 1182 
complaint.  A device malfunction is any failure of a device to meet its performance specifications 1183 
or otherwise perform as intended.  Performance spec ifications include all claims made in the 1184 
labeling for the device.  The intended performance of a device refers to the intended use for 1185 
which the device is labeled or marketed. (21 CFR 80 3.3).  Note: for reporting purposes, sites will [ADDRESS_320128] medical occurrence that 1189 
meets one of the following criteria: 1190 
• An SAE 1191 
• An ADE as defined in section 9.2.1, unless excluded  from reporting in section 9.3 1192 
• An AE as defined in 9.2.1 occurring in association with a study procedure 1193 
• An AE as defined in 9.2.1 not related to a device i ssue which leads to temporary or 1194 
permanent discontinuation of  a study device 1195 
• An AE as defined in 9.2.1 for which a visit is made  to a hospi[INVESTIGATOR_3409]   1196 
• Hypoglycemia meeting the definition of severe hypog lycemia as defined below 1197 
• Diabetic ketoacidosis (DKA) as defined below or in the absence of DKA, hyperglycemia [ADDRESS_320129].  Skin reactions from sensor placement 1201 
are only reportable if severe and/or required treat ment. 1202 
All reportable AEs—whether volunteered by [CONTACT_17071], discovered by [CONTACT_3462] [ADDRESS_320130], or other means— [ADDRESS_320131] is only reportable as an adverse 1208 
event when the following definition for severe hypo glycemia is met: the event required 1209 
assistance of another person due to altered conscio usness, and required another person to actively 1210 
administer carbohydrate, glucagon, or other resusci tative actions.  This means that the participant 1211 
was impaired cognitively to the point that he/she w as unable to treat himself/herself, was unable 1212 
to verbalize his/ her needs, was incoherent, disori ented, and/or combative, or experienced seizure 1213 
or loss of consciousness.  These epi[INVESTIGATOR_263213] 1214 
induce seizure or loss of consciousness.  If plasma  glucose measurements are not available 1215 
during such an event, neurological recovery attribu table to the restoration of plasma glucose to 1216 
normal is considered sufficient evidence that the e vent was induced by a low plasma glucose 1217 
concentration. 1218 
When a hypoglycemic event meets the above reporting  requirements, a Hypoglycemia Form 1219 
should be completed in addition to the Adverse Even t Form. Severe hypoglycemia events are 1220 
considered to be serious adverse events with respec t to reporting requirements. 1221 
9.2.4  Hyperglycemic/Ketotic Events [ADDRESS_320132] is only reportable as an adverse 1223 
event when one of the following 4 criteria is met: 1224 
The event involved DKA, as defined by [CONTACT_3467] 1225 
(DCCT) and described below 1226 
Evaluation or treatment was obtained at a health ca re provider facility for an acute event 1227 
involving hyperglycemia or ketosis, or the particip ant contact[CONTACT_3466] 1228 
guidance on how to manage the hyperglycemia/ketosis  1229 
Blood ketone level ≥1.0 mmol/L, even if there was no communication with  a health care 1230 
provider (may not be identified until ketone meter data are uploaded)  1231 
Hyperglycemic events are classified as DKA if the f ollowing are present: 1232 
Symptoms such as polyuria, polydipsia, nausea, or v omiting; 1233 
Serum ketones >1.5 mmol/L or large/moderate urine k etones; 1234 
Either arterial blood pH <7.30 or venous pH <7.24 o r serum bicarbonate <15; and 1235 
Treatment provided in a health care facility. 1236 
When a hyperglycemia/ketotic event meets the above reporting requirements, a 1237 
Hyperglycemia/DKA Form should be completed in addit ion to the Adverse Event Form. Events [ADDRESS_320133] been caused 1244 
by [CONTACT_19911]. 1245 
To ensure consistency of adverse event causality as sessments, investigators should apply the 1246 
following general guideline when determining whethe r an adverse event is related: 1247 
Yes 1248 
There is a plausible temporal relationship between the onset of the adverse event and the study 1249 
intervention, and the adverse event cannot be readi ly explained by [CONTACT_2299]’s clinical state, 1250 
intercurrent illness, or concomitant therapi[INVESTIGATOR_014]; and /or the adverse event follows a known pattern 1251 
of response to the study intervention; and/or the a dverse event abates or resolves upon 1252 
discontinuation of the study intervention or dose r eduction and, if applicable, reappears upon 1253 
re-challenge. 1254 
No 1255 
Evidence exists that the adverse event has an etiol ogy other than the study intervention 1256 
(e.g., preexisting medical condition, underlying di sease, intercurrent illness, or concomitant 1257 
medication); and/or the adverse event has no plausi ble temporal relationship to study 1258 
intervention. 1259 
9.2.6  Severity (Intensity) of Adverse Events 1260 
The severity (intensity) of an adverse event will b e rated on a three point scale: (1) mild, 1261 
(2) moderate, or (3) severe.  A severity assessment  is a clinical determination of the intensity of 1262 
an event.  Thus, a severe adverse event is not nece ssarily serious.  For example, itching for 1263 
several days may be rated as severe, but may not be  clinically serious. 1264 
MILD: Usually transient, requires no special treatm ent, and does not interfere with the 1265 
participant’s daily activities. 1266 
MODERATE: Usually causes a low level of inconvenien ce, discomfort or concern to the 1267 
participant and may interfere with daily activities , but is usually ameliorated by [CONTACT_3469] 1268 
therapeutic measures and participant is able to con tinue in study. 1269 
SEVERE: Interrupts a participant’s usual daily acti vities, causes severe discomfort, may 1270 
cause discontinuation of study device, and generall y requires systemic drug therapy or other 1271 
treatment. 1272 
9.2.7  Expectedness 1273 
For a serious adverse event that is considered poss ibly related to study device, the Medical 1274 
Monitor will classify the event as unexpected if th e nature, severity, or frequency of the event is 1275 
not consistent with known risk information.  1276 
9.2.8  Coding of Adverse Events 1277 
Adverse events will be coded using the MedDRA dicti onary. To facilitate coding, the clinical 1278 
investigator will enter a preliminary MedDRA code w hich the Medical Monitor may accept or 1279 
change (the Medical Monitor’s MedDRA coding will be  used for all reporting). The Medical 1280 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 61  OF 97 Monitor will review the investigator’s assessment o f causality and may agree or disagree.  Both 1281 
the investigator’s and Medical Monitor’s assessment s will be recorded.  The Medical Monitor [ADDRESS_320134] the final say in determining the causalit y as well as whether an event is classified as a 1283 
serious adverse event and/or an unanticipated adver se device effect. 1284 
9.2.9  Outcome of Adverse Events 1285 
The outcome of each reportable adverse event will b e classified by [CONTACT_3470]: 1286 
RECOVERED/RESOLVED: The participant recovered from the AE/SAE without sequelae.  [ADDRESS_320135] the AE/SAE stop date. 1288 
RECOVERED/RESOLVED WITH SEQUELAE: The event persist ed and had stabilized [ADDRESS_320136] th e AE/SAE stop date. 1290 
FATAL: A fatal outcome is defined as the SAE that r esulted in death.  Only the event that 1291 
was the cause of death should be reported as fatal.   AEs/SAEs that were ongoing at the time 1292 
of death; however, were not the cause of death, wil l be recorded as “resolved” at the time of 1293 
death. 1294 
NOT RECOVERED/NOT RESOLVED (ONGOING): An ongoing AE /SAE is defined as the 1295 
event was ongoing with an undetermined outcome. 1296 
An ongoing outcome will require follow-up by [CONTACT_171691] 1297 
outcome of the AE/SAE. 1298 
The outcome of an ongoing event at the time of deat h that was not the cause of death, will be 1299 
updated and recorded as “resolved” with the date of  death recorded as the stop date. 1300 
UNKNOWN: An unknown outcome is defined as an inabil ity to access the participant or the 1301 
participant’s records to determine the outcome (for  example, a participant that was lost to 1302 
follow-up). 1303 
If any reported adverse events are ongoing when a p articipant completes the study 1304 
(or withdraws), adverse events classified UADEs wil l be followed until they are either [ADDRESS_320137] of improvement or cha nge, even after the participant has 1306 
completed all applicable study visits/contacts.  Fo r all other adverse events, data collection will 1307 
end at the time the participant completes the study . Note: participants should continue to receive 1308 
appropriate medical care for an adverse event after  their participation in the study ends.  1309 
9.3  Reportable Device Issues 1310 
All UADEs and ADEs as defined in section 9.1.1 will  be reported on both a device issue form 1311 
and AE form, except for skin reactions from CGM sen sor placement or pump infusion set 1312 
placement that do not require pharmacologic treatme nt. As noted in section 9.1.1, events that 1313 
occur due to participant (user) error generally wil l not require completion of a device issue form. 1314 
Such ‘errors’ could include improper use of an insu lin pump or using a pump infusion set or [ADDRESS_320138] not b een met: 1319 
CGM sensor lasting fewer days than expected per man ufacturer 1320 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 62  OF 97 CGM tape adherence issues 1321 
Battery lifespan deficiency due to inadequate charg ing or extensive wireless 1322 
communication 1323 
Intermittent device component disconnections/commun ication failures not requiring 1324 
system replacement or workaround/resolution not spe cified in user guide/manual [ADDRESS_320139] be reported to 1329 
the Coordinating Center within 24 hours of the site  becoming aware of the event.  This can occur 1330 
via phone or email, or by [CONTACT_263240] 1331 
form if applicable.  If the form is not initially c ompleted, it should be competed as soon as 1332 
possible after there is sufficient information to e valuate the event. All other reportable ADEs and 1333 
other reportable AEs should be submitted by [CONTACT_263241] 7 days of the 1334 
site becoming aware of the event. 1335 
The Coordinating Center will notify all participati ng investigators of any adverse event that is 1336 
serious, related, and unexpected.  Notification wil l be made within 10 days after the 1337 
Coordinating Center becomes aware of the event. 1338 
Each principal investigator [INVESTIGATOR_171663]-related adverse events and 1339 
abiding by [CONTACT_263242] c to his/her Institutional Review Board or 1340 
Ethics Committee. 1341 
Upon receipt of a UADE report, the Sponsor will inv estigate the UADE and if indicated, report 1342 
the results of the investigation to the sites’ IRBs , and the FDA within 10 working days of the 1343 
Sponsor becoming aware of the UADE per 21CFR 812.46 (b) (2).  The Medical Monitor must [ADDRESS_320140] receipt notice of the UADE. 1348 
Device malfunctions will be handled by [CONTACT_263243].  In the case 1349 
of a CGM transmitter or sensor device malfunction, information will be forwarded to Dexcom by 1350 
the site personnel, to be handled by [CONTACT_263244] t management system. 1351 
9.5  Reporting to Novo Nordisk 1352 
For NovoLog: Copi[INVESTIGATOR_263214] .   1353 
For Fiasp: 1354 
• Copi[INVESTIGATOR_263214]. 1355 
• All non-serious adverse events  1356 
• All Serious adverse events 1357 
• All events of pregnancy 1358 
• All technical issues with the product alone, all te chnical issues with the combined 1359 
system (pump and Fiasp) and all issues with the pac kaging material and labelling 1360 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 63  OF 97 Prompt notification to Novo Nordisk of a SAE by [CONTACT_263245] 1361 
Nordisk’s legal obligations and ethical responsibil ities towards the safety of participants and the [ADDRESS_320141] (IRB), independent ethics committee (I EC), and investigators. 1367 
Drug related UADEs will also be reported to Novo No rdisk by [CONTACT_57952] 15 1368 
days of the Coordinating Center’s first knowledge o f the event. At a minimum, the following 1369 
should be reported: Study name, Patient identificat ion (e.g. subject number, sex, age), Event 1370 
(Preferably diagnosis), Trial drug, Reporter, Causa lity, and Outcome.  1371 
9.6  Safety Oversight 1372 
The study Medical Monitor will review all adverse e vents and adverse device events that are 1373 
reported during the study.  SAEs typi[INVESTIGATOR_66684] 24 hours of reporting.  1374 
Other AEs typi[INVESTIGATOR_3413] a weekly ba sis. Additionally, the Medical Monitor will 1375 
review compi[INVESTIGATOR_27985] ( generally timed to the review of compi[INVESTIGATOR_42602] 1376 
safety data by [CONTACT_4318]). 1377 
The Clinical Study Director will be informed of all  cases of severe hypoglycemia and DKA 1378 
and the Medical Monitor’s assessment of relationshi p to the study device; and informed of all [ADDRESS_320142] (DSMB) will prov ide safety oversight.  The DSMB will be [ADDRESS_320143] modifications to the study pro tocol or suspension or outright stoppage of 1386 
the study if deemed necessary based on the totality  of safety data available.  Details regarding the 1387 
DSMB’s role will be documented in a separate DSMB d ocument. 1388 
9.7  Stoppi[INVESTIGATOR_2121] 1389 
In the case of an unanticipated system malfunction resulting in a severe hypoglycemia or DKA 1390 
event (or a malfunction that could have led to seve re hypoglycemia or DKA), use of the BP 1391 
system will be suspended while the problem is diagn osed. The UADE will be reported to the 1392 
IRB, DSMB, and FDA. After assessment of the problem  and any correction,  use of the system 1393 
will not be restarted until approval is received fr om the IRB, DSMB, and FDA. 1394 
In the absence of a device malfunction, use of the BP system by a participant will be 1395 
discontinued if any of the following occur: 1396 
The investigator believes it is unsafe for the part icipant to continue on the intervention.  1397 
This could be due to the development of a new medic al condition or worsening of an 1398 
existing condition; or participant behavior contrar y to the indications for use of the 1399 
device that imposes on the participant’s safety  [ADDRESS_320144] to determination of cause and whe ther the occurrence of the event can be 1408 
attributed to use of the BP system.  1409 
An additional requirement for continued system use following a single DKA or severe 1410 
hypoglycemia event will be that (1) the site invest igator believes that the event is explainable, 1411 
unlikely to recur, and that it is safe for the part icipant to continue to use the system and (2) the 1412 
Medical Monitor and DSMB concur. If either the Medi cal Monitor or DSMB determines that the 1413 
occurrence of the event indicates that it is not sa fe for the participant to continue to use the BP 1414 
system, use will be discontinued. 1415 
9.7.1  Criteria for Suspending or Stoppi[INVESTIGATOR_3396] 1416 
In addition to the suspension of device use due to a UADE as described in 9.7, study activities 1417 
could be similarly suspended if the manufacturer of  any constituent study device requires 1418 
stoppage of device use for safety reasons (e.g. pro duct recall).  The affected study activities may [ADDRESS_320145] suspens ion of study activities or stoppage of the 1422 
study if deemed necessary based on the totality of safety data available. 1423 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 65  OF 97 Chapter 10:  Miscellaneous Considerations 1424 
10.1  Collection of Medical Conditions and Medications 1425 
Pre-Existing Conditions:  Collection of pre-existing conditions will include  any medical [ADDRESS_320146] the participant’s health during the course o f the study (e.g., prior myocardial infarction or 1428 
stroke). 1429 
Medical Conditions during the study:  The following medical conditions that do not quali fy for 1430 
reporting on an Adverse Event Form should be report ed on the Medical Conditions Form: 1431 
(1) new diagnosis of a chronic disease (i.e., not p resent at the time of enrollment) and (2) any [ADDRESS_320147] the participant ’s ability to carry out any aspect of the protocol [ADDRESS_320148] the participant’s 1434 
ability to carry out the protocol or study data rel ated to any study outcome do not need to be 1435 
reported. 1436 
Medications:  All medications that the participant is currently taking at screening and during the 1437 
course of the study should be recorded.  Nutraceuti cals and preventative treatment also should be 1438 
recorded.  This will include the treatment of chron ic pre-existing conditions, medical conditions 1439 
that occur during the study (both reportable and no t-reportable medical conditions), and/or 1440 
adverse events. Medications only taken as needed ei ther can be recorded when prescribed or only 1441 
recorded if used during the study.  Glucagon for tr eatment of severe hypoglycemia will only be 1442 
recorded if used during the study. 1443 
10.2  Prohibited Medications, Devices, Treatments and Pro cedures 1444 
Participants are not permitted to initiate use of a  blood glucose lowering medication that was not 1445 
in use and met eligibility criteria at the time of screening.  This includes but is not limited to 1446 
SGLT2 inhibitor, sulfonylurea, GLP1, pramlintide, o r metformin drugs. 1447 
Participants are not permitted to use diabetes mana gement devices that are not FDA approved 1448 
(such as do-it-yourself closed-loop systems). [ADDRESS_320149] a commerc ially available glucagon (or glucagon analog) 1451 
preparation for treatment as needed of severe hypog lycemia. 1452 
10.4  Pregnancy Reporting 1453 
If pregnancy occurs, the study intervention will be  discontinued while continuing safety 1454 
follow-up.  The occurrence of pregnancy will be rep orted to the Coordinating Center and to the 1455 
JCHR IRB on the Unanticipated Problem form within 7  calendar days of becoming aware of the 1456 
pregnancy. 1457 
10.5  Participant Compensation 1458 
Participant compensation will be described in the i nformed consent form. 1459 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 66  OF 97 10.6  Participant Withdrawal 1460 
Participation in the study is voluntary, and a part icipant may withdraw at any time.  1461 
For participants who withdraw, their data will be u sed up until the time of withdrawal. 1462 
For participants using the BP who withdraw, a study  provider will help them transition to their 1463 
own CSII or MDI therapy safely. 1464 
10.7  Confidentiality 1465 
For security and confidentiality purposes, particip ants will be assigned identifiers that will be 1466 
used instead of their names.  Protected health info rmation gathered for this study will be shared 1467 
with the Coordinating Center, the Jaeb Center for H ealth Research in Tampa, FL.  De-identified 1468 
participant information may also be provided to res earch sites involved in the study. 1469 
 1470 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 67  OF 97 Chapter 11:  Statistical Considerations 1471 
11.1  Statistical and Analytical Plans 1472 
The approach to sample size and statistical analyse s are summarized below. A detailed statistical 1473 
analysis plan will be written and finalized prior t o the start of the study. 1474 
11.2  Statistical Hypotheses 1475 
The primary outcome is: 1476 
• Superiority in HbA1c at 13 weeks 1477 
 1478 
A key secondary outcome is 1479 
• Non-inferiority in CGM-measured time <54 mg/dL calc ulated over 13 weeks 1480 
Only superiority in HbA1c at 13 weeks needs to be m et to declare efficacy. Primary outcome 1481 
analyses will combine pediatric and adult participa nts into a single analysis.  The study 1482 
hypotheses can be stated as follows: 1483 
HbA1c Outcome: 1484 
• Null Hypothesis : There is no difference in the mean HbA1c at 13 we eks between BP 1485 
aspart/lispro and Control Group  1486 
• Alternative Hypothesis : There is a nonzero difference in the mean HbA1c a t 13 weeks 1487 
between BP aspart/lispro and Control Group  1488 
Time <54 mg/dL Outcome: 1489 
• Null Hypothesis : There is a mean difference of at least 1% in the percentage of time spent 1490 
with a sensor glucose level below 54 mg/dL between the BP aspart/lispro and Control 1491 
Group over the 13 weeks 1492 
• Alternative Hypothesis : There is a mean difference of less than 1% in the  percentage of 1493 
time spent with a sensor glucose level below 54 mg/ dL between the BP aspart/lispro and 1494 
Control Group over the 13 weeks 1495 
The primary analyses will include only the BP aspar t/lispro Groups compared with the Control [ADDRESS_320150] to dif ferent age groups and to use of both insulin 1502 
aspart/lispro and Fiasp.  RCT completion is expecte d for 200 participants randomized to BP 1503 
aspart/lispro Group, 100 to the BP Fiasp Group, and  100 to the Control Group. 1504 
The primary analysis for BP aspart/lispro vs. Contr ol Group will include both the pediatric and 1505 
adult participants in a single analysis. Superiorit y for HbA1c at 13 weeks and non-inferiority for 1506 
time <54 mg/dL measured with CGM at intervals over the 13 weeks are considered primary 1507 
endpoints.  Statistical power for each endpoint was  computed assuming the following: 1508 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 68  OF 97 HbA1c: Statistical power is >99%, assuming true mea n HbA1c difference of 0.4% between BP 1509 
aspart/lispro and Control Group, standard deviation  of 13-week HbA1c of 0.8%, correlation 1510 
between baseline and 13-week HbA1c of 0.40, two-sid ed type 1 error of 5% 1511 
Time <54 mg/dL: Statistical power is 99%, assuming no true difference in mean time <54 mg/dL 1512 
between BP aspart/lispro and Control Group, a non-i nferiority margin of 1%, standard deviation 1513 
of percent time <54 mg/dL of 2.0%, correlation betw een baseline and follow-up of 0.40, and 1514 
one-sided type 1 error of 0.025% 1515 
Power calculations comparing BP Fiasp and Control G roup  are described in Section 11.12.  1516 
11.4  Efficacy Outcome Measures 1517 
11.4.1  Primary and Key Secondary Efficacy Endpoints 1518 
HbA1c at 13 weeks (superiority) 1519 
CGM time < 54 mg/dL (non-inferiority) [ADDRESS_320151].  If the HbA1c analysis results in a statistically significant 1522 
result (p < 0.05), then testing will proceed to the  CGM time <54 mg/dL analysis. 1523 
11.4.2  Additional Secondary Efficacy Endpoints 1524 
[IP_ADDRESS]  Secondary Efficacy Endpoints Included in Hierarchic al Analysis 1525 
Assuming the primary and key secondary endpoints me et statistical significance as described 1526 
above, the following CGM-measured secondary endpoin ts will be tested for superiority in a 1527 
hierarchical fashion as described in Section 11.6.4 . 1528 
Mean glucose 1529 
Time 70-180 mg/dL 1530 
Time >180 mg/dL 1531 
Time >250 mg/dL [ADDRESS_320152] deviation 1533 
Time <70 mg/dL 1534 
Time <54 mg/dL 1535 
Coefficient of variation 1536 
[IP_ADDRESS]  Other Secondary Efficacy Endpoints 1537 
The following endpoints are considered exploratory.  Type 1 error for these endpoints will be 1538 
controlled using the false discovery rate (FDR).  T he Fiasp and aspart/lispro groups will be 1539 
pooled for analyses of the secondary efficacy endpo ints listed in this section if there are not 1540 
statistically significant differences comparing the  Fiasp and aspart/lispro groups for the primary 1541 
and key secondary outcomes, as described in section  11.14.  1542 
HbA1c: 1543 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 69  OF 97 HbA1c <7.0% at 13 weeks 1544 
HbA1c <7.0% at 13 weeks in participants with baseli ne HbA1c >7.5% 1545 
HbA1c <7.5% at 13 weeks 1546 
HbA1c <8.0% at 13 weeks 1547 
HbA1c >9.0% at 13 weeks 1548 
HbA1c improvement from baseline to 13 weeks >0.5% 1549 
HbA1c improvement from baseline to 13 weeks >1.0% 1550 
HbA1c relative improvement from baseline to 13 week s >10% 1551 
HbA1c improvement from baseline to 13 weeks >1.0% o r HbA1c <7.0% at 13 weeks 1552 
CGM-Measured: 1553 
Time in range 70-140 mg/dL 1554 
Time in range 70-120 mg/dL 1555 
Time <60 mg/dL 1556 
Area over the curve (70 mg/dL) 1557 
Low blood glucose index 1558 
CGM-measured hypoglycemic events ( ≥15 minutes with glucose concentration <54 1559 
mg/dL) 1560 
CGM-measured hyperglycemic events ( ≥15 minutes with glucose concentration >300 1561 
mg/dL) 1562 
Time >300 mg/dL  1563 
Area under the curve (180 mg/L) 1564 
High blood glucose index 1565 
Time in range 70-180 mg/dL >70% 1566 
Time in range 70-180 mg/dL improvement from baselin e to 13 weeks ≥5% 1567 
Time in range 70-180 mg/dL improvement from baselin e to 13 weeks ≥10% 1568 
Mean of daily difference (MODD) 1569 
Time <70 mg/dL <4% 1570 
Time <54 mg/dL <1% 1571 
Combined Secondary Outcomes: 1572 
Improvement in HbA1c > 0.5% without an increase in time < 54 mg/dl by > 0.5% OR 1573 
improvement in time < 54 mg/dl by > 0.5% without an  increase in HbA1c by > 0.5% 1574 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 70  OF 97 Improvement in time 70–180 mg/dl by >10% without an  increase in time < 54 mg/dl by > 1575 
0.5%  OR improvement in time < 54 mg/dl by > 0.5% w ithout a decrease in time 70–180 1576 
mg/dl by > 10% 1577 
BGRI = LBGI + HBGI 1578 
Mean glucose <154 mg/dL and time <54 mg/dL <1%  1579 
Time in range 70-180 mg/dL >70% and time <54 mg/dL <1% 1580 
Other Secondary Outcomes: 1581 
Questionnaires scores on each questionnaire that is  administered (see chapter 8) 1582 
Insulin 1583 
o Total daily insulin (units/kg) [ADDRESS_320153] two-week period (iLet Gr oup only) 1586 
Weight and Body Mass Index (BMI)  1587 
From the weekly questionnaires, number of hypoglyce mic events requiring carbohydrate 1588 
treatment per 24 hours 1589 
From the weekly questionnaires, grams of carbohydra te taken specifically to treat 1590 
hypoglycemic events per 24 hours 1591 
11.5  CGM Metrics Calculations 1592 
Baseline values for each CGM metric will be compute d from either the participant’s personal [ADDRESS_320154],  CGM metrics will be calculated fro m the CGM data collected from the Control 1596 
Group for comparison with the CGM data from the BP Group.  Percentage of CGM values that 1597 
fall within a specified range will be calculated by  [CONTACT_263246] 1598 
within the range by [CONTACT_263247] s.  1599 
11.6  Analysis of the Primary and Secondary Efficacy Endp oints 1600 
The primary analysis will include both the pediatri c and adult participants in a single analysis.  1601 
All analyses comparing the BP aspart/lispro with th e Control Group will follow the intention-to- 1602 
treat (ITT) principle with the data from each parti cipant analyzed according to the treatment 1603 
assigned by [CONTACT_17628].   1604 
A per-protocol analysis that includes participants adhering to the protocol will be performed and 1605 
detailed in the SAP.  Sensitivity analyses on the p rimary and key secondary outcomes also will 1606 
be described in the SAP. 1607 
11.6.1  HbA1c Analyses (Superiority) 1608 
HbA1c at 13 weeks will be compared between the BP a spart/lispro and Control Groups using a 1609 
linear mixed effects regression model adjusting for  baseline HbA1c, age, and clinical center 1610 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 71  OF 97 (random factor).  HbA1c is expected to be normally distributed, but regression diagnostics will [ADDRESS_320155] likelihood to incorporate information 1615 
from baseline measurements to calculate the maximum  likelihood at 13 weeks. Only central lab 1616 
HbA1c measurements will be used in the analyses. 1617 
Other secondary HbA1c outcomes will be tested and d escribed in the SAP. 1618 
11.6.2  Time <54 mg/dL (Noninferiority) 1619 
Time below 54 mg/dL will be calculated over [ADDRESS_320156] as described in 1620 
Section11.5.  A two-sided 95% confidence interval o n the mean difference in % time <54 mg/dL 1621 
between BP aspart/lispro and Control Group will be performed based on a linear mixed effects 1622 
regression model adjusting for baseline % time <54 mg/dL, age, and clinical center (random 1623 
factor).  Noninferiority will be assessed by [CONTACT_263248] 1624 
interval to a noninferiority limit of 1%.  Missing data will be handled by [CONTACT_263249] 1625 
likelihood.  Residuals values will be examined for an approximate normal distribution.  If the 1626 
values are highly skewed, then a transformation or nonparametric method will be used instead.  1627 
A two-sided p-value will be reported, and a 5% sign ificance level will be used to declare [ADDRESS_320157] at alpha = 0.[ADDRESS_320158] at alpha 1631 
= 0.025.  Therefore, reporting a two-sided 95% conf idence interval will provide flexibility to test 1632 
for inferiority if noninferiority cannot be declare d while maintaining the overall type 1 error rate 1633 
of 5%. 1634 
11.6.3  Secondary CGM Metrics (Superiority) 1635 
Summary statistics (mean ± SD or median (quartiles) ) will be reported for the CGM-measured 1636 
metrics at baseline and during follow up as well as  for differences from baseline by [CONTACT_3148] 1637 
group. 1638 
Secondary CGM metrics will be calculated as describ ed in Section 11.5.  CGM metric 1639 
differences between BP and Control Groups will be c ompared using a linear mixed effects 1640 
regression model adjusting for the baseline value o f the metric, age, and clinical center (random [ADDRESS_320159]).  Residual values will be examined for an a pproximate normal distribution.  If residuals [ADDRESS_320160] statistical method (e.g., non-parametric or 1643 
MM estimation) will be used instead. Missing data w ill be handled using direct likelihood. 1644 
11.6.4  Hierarchical Analyses 1645 
To preserve the overall type 1 error for the primar y endpoint and key secondary endpoint as 1646 
defined in section 11.4.1 and selected secondary en dpoints listed in section [IP_ADDRESS], a 1647 
hierarchical testing procedure will be used.  If th e primary analysis for HbA1c results in a 1648 
statistically significant result (p < 0.05), then t esting at the 0.[ADDRESS_320161] will not be formally te sted. 1653 
Regardless of the results of the hierarchical testi ng, summary statistics appropriate to the 1654 
distribution will be tabulated by [CONTACT_1570] f or each hierarchical outcome.  A 95% [ADDRESS_320162]- 1669 
randomization safety events will be reported.  Sepa rately, any adverse events occurring between 1670 
screening and randomization will be reported. 1671 
All reportable adverse events will be tabulated by [CONTACT_1570] (aspart/lispro and Fiasp 1672 
groups will be reported separately).  Details will be provided in a listing of each event, including 1673 
Medical Dictionary for Regulatory Activities (MedDR A) term and MedDRA System Organ [ADDRESS_320163].  1676 
Formal statistical testing only will be performed f or selected safety endpoints. For the following 1677 
outcomes, mean ± SD or summary statistics appropria te to the distribution will be tabulated by 1678 
treatment group and formal statistical comparisons will be performed if there are enough events 1679 
(at least 5 events combined between the BP aspart/l ispro and Control Group): 1680 
Number of SH events and SH event rate per 100 perso n-years 1681 
Number of DKA events and DKA event rate per 100 per son-years 1682 
Other serious adverse events 1683 
Worsening of HbA1c from baseline to 13 weeks by >0. 5% [ADDRESS_320164] Poisson regression as  detailed in the SAP.   1687 
Since the Control Group is not provided with a stud y blood glucose meter or blood ketone meter, 1688 
no treatment group comparisons of meter data will b e performed.  Additionally, no formal 1689 
statistical comparison will be made of all reported  adverse events combined since there are 1690 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 73  OF 97 specific requirements in the protocol for reporting  certain events in real-time for the BP Group 1691 
but not the Control Group, and adverse device effec ts are only reported for the BP Group. 1692 
11.7.1  Safety Tabulations Specific to the BP Group 1693 
For the BP Group, all of the following will be tabu lated separately for the BP aspart/lispro Group 1694 
and the Fiasp Group: 1695 
Adverse device effects (ADE) 1696 
Serious adverse device events (SADE) 1697 
Unanticipated adverse device effects (UADE) 1698 
11.8  Additional Tabulations and Analyses 1699 
The following tabulations will be performed accordi ng to treatment group: 1700 
Baseline demographics and clinical characteristics 1701 
A flow chart accounting for all participants for al l visits 1702 
Visit completion rates for each follow-up visit 1703 
Protocol deviations 1704 
Modifications in diabetes management class in the C ontrol Group (e.g. change between 1705 
MDI/CSII) during the study  1706 
Number and reasons for unscheduled visits and phone  calls 1707 
11.8.1  Tabulations Specific to the BP Group 1708 
Number of participants who stopped BP use and reaso ns 1709 
% time in closed loop [ADDRESS_320165] an d other reported device issues 1712 
11.9  Planned Interim Analyses 1713 
No formal interim efficacy analyses are planned as study recruitment is expected to be rapid and 1714 
the duration of follow up short.  The DSMB will rev iew safety data at intervals, with no formal 1715 
stoppi[INVESTIGATOR_263215] i n the participant-level and study-level stoppi[INVESTIGATOR_007] 1716 
criteria (as defined in Section 9.6 of the protocol ). [ADDRESS_320166], the efficacy and safety  analyses will be performed in preparation 1719 
for PMA submission. 1720 
11.10  Subgroup Analyses 1721 
In exploratory analyses, the primary and key second ary outcomes plus time in range 70-180 1722 
mg/dL and mean glucose will be assessed separately for interaction with certain baseline 1723 
variables, including baseline HbA1c, prior pump/CGM  use, and other baseline characteristics as 1724 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 74  OF 97 described in the SAP.  The Fiasp and aspart/lispro Groups will be pooled if there are not 1725 
statistically significant differences comparing the  Fiasp and aspart/lispro Groups for the primary 1726 
endpoints as described in section 11.14, with the e xception of subgroup analyses by [CONTACT_654], in 1727 
which only the BP aspart/lispro group will be compa red with the Control Group. All primary and 1728 
key secondary variables will be evaluated in the pr edefined age groups (>18 years old and <18 1729 
years old, and further subdivided as 6-<13, 13-<18,  18-<26, 26-<50, >50 years 1730 
old).Interpretation of the subgroup analyses will b e made with caution, particularly if the primary 1731 
analysis is not significant.  1732 
11.11  Multiple Comparison/Multiplicity 1733 
Hierarchical Analyses 1734 
The hierarchical testing procedure described above in Section 11.6.1 will be used to control the 1735 
overall type 1 error for the primary endpoint and k ey secondary endpoints plus eight additional 1736 
secondary outcomes identified above. 1737 
All Other Secondary Analyses 1738 
For the other secondary analyses, the false discove ry rate will be controlled using the adaptive 1739 
Benjamini-Hochberg procedure. 1740 
11.12  Additional Exploratory Analyses 1741 
Additional analyses comparing treatment groups will  include: 1742 
Comparison of aspart/lispro BP Group versus Control  Group in adults >[ADDRESS_320167] variability of HbA1c  1747 
11.13  BP Fiasp Versus Control Group 1748 
All of the above analyses with the exception of sub group analyses by [CONTACT_263250] 1749 
replicated comparing the BP Fiasp and Control Group s.  This analysis will be treated as a 1750 
separate study, so the multiple hypothesis testing in the BP aspart/lispro vs Control comparison 1751 
will not be adjusted for the BP Fiasp vs. Control G roup comparison.  However, the same 1752 
hierarchical testing procedure will be performed fo r the BP Fiasp versus Control comparison for 1753 
primary and secondary endpoints and the false disco very rate will be controlled for the other 1754 
secondary endpoints as described in Section 11.11. 1755 
This analysis will include approximately 100 partic ipants in BP Fiasp and 50 participants in 1756 
Control Group. Statistical power for each primary e ndpoint was computed assuming the 1757 
following: 1758 
HbA1c: Statistical power is 91%, assuming true mean  HbA1c difference of 0.4% between BP [ADDRESS_320168] deviation of 13-w eek HbA1c of 0.8%, correlation between 1760 
baseline and 13-week HbA1c of 0.40, two-sided type 1 error of 5% 1761 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 75  OF 97 Time <54 mg/dL: Statistical power is 86%, assuming no true difference in mean time <54 mg/dL 1762 
between BP Fiasp and Control Group, a non-inferiori ty margin of 1%, standard deviation of 1763 
percent time <54 mg/dL of 2.0%, correlation between  baseline and follow-up of 0.40, and one- 1764 
sided type 1 error of 0.025% 1765 
11.14  Comparison of Aspart/Lispro Group and Fiasp Group 1766 
For the primary and key secondary endpoints, the BP  aspart/lispro Group and the BP Fiasp 1767 
Group will be compared.  If neither analysis has a p value >0.[ADDRESS_320169]. 1774 
Analyses will be considered exploratory.  The prima ry analyses will be for safety, tabulating 1775 
events.  Exploratory analyses will include mean CGM  glucose level and time of CGM measured 1776 
time < 54 mg/dL. 1777 
 1778 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 76  OF 97 Chapter 12:  Data Collection and Monitoring 1779 
12.1  Case Report Forms and Other Data Collection 1780 
The main study data are collected on electronic cas e report forms (eCRFs).  When data are 1781 
directly collected in electronic case report forms,  this will be considered the source data.  For any 1782 
data points for which the eCRF is not considered so urce (e.g. lab results that are transcribed from 1783 
a printed report into the eCRF), the original sourc e documentation will be maintained in the 1784 
participant’s study chart or medical record.  This source must be readily verifiable against the [ADDRESS_320170] be recorded (e.g., office note, visit record,  1787 
etc.). 1788 
Electronic device data files are obtained from the study software and individual hardware 1789 
components.  These electronic device files are cons idered the primary source documentation. 1790 
HbA1c measurements will be made by [CONTACT_263251] 1791 
the Coordinating Center. 1792 
12.2  Study Records Retention 1793 
Each participating site will maintain appropriate m edical and research records for this trial, in 1794 
compliance with ICH E6 and regulatory and instituti onal requirements for the protection of 1795 
confidentiality of participants. 1796 
Study documents should be retained for a minimum of  3 years after the final NIH grant 1797 
reporting.  These documents should be retained for a longer period, however, if required by [CONTACT_5737] 1798 
regulations.  No records will be destroyed without the written consent of the sponsor, if 1799 
applicable.  It is the responsibility of the sponso r to inform the investigator when these 1800 
documents no longer need to be retained. 1801 
12.3  Quality Assurance and Monitoring 1802 
Designated personnel from the Coordinating Center w ill be responsible for maintaining quality 1803 
assurance (QA) and quality control (QC) systems to ensure that the clinical portion of the trial is 1804 
conducted and data are generated, documented and re ported in compliance with the protocol, 1805 
Good Clinical Practice (GCP) and the applicable reg ulatory requirements, as well as to ensure 1806 
that the rights and wellbeing of trial participants  are protected and that the reported trial data are  1807 
accurate, complete, and verifiable.  Adverse events  will be prioritized for monitoring. 1808 
A risk-based monitoring (RBM) plan will be develope d and revised as needed during the course 1809 
of the study, consistent with the FDA “Guidance for  Industry Oversight of Clinical 1810 
Investigations—A Risk-Based Approach to Monitoring”  (August 2013).  Study conduct and 1811 
monitoring will conform with 21 Code of Federal Reg ulations (CFR) 812.  This plan describes in [ADDRESS_320171] importance for monitoring at the s ite are participant eligibility and adverse 1815 
events.  Therefore, the RBM plan will focus on thes e areas.  As much as possible, remote 1816 
monitoring will be performed in real-time with on-s ite monitoring performed to evaluate the 1817 
verity and completeness of the key site data.  Elem ents of the RBM may include: [ADDRESS_320172] (IRB) cover age and informed consent 1820 
procedures 1821 
Central (remote) data monitoring: validation of dat a entry, data edits/audit trail, protocol 1822 
review of entered data and edits, statistical monit oring, study closeout 1823 
On-site monitoring (site visits): source data verif ication, site visit report 1824 
Agent/Device accountability [ADDRESS_320173] access to all trial related sites, source 1835 
data/documents, and reports for the purpose of moni toring and auditing by [CONTACT_456], and 1836 
inspection by [CONTACT_3482]. 1837 
12.4  Protocol Deviations 1838 
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or procedure 1839 
requirements.  As a result of deviations, correctiv e actions are to be developed by [CONTACT_5753] 1840 
implemented promptly. 1841 
The site PI/study staff is responsible for knowing and adhering to their IRB requirements.  1842 
Further details about the handling of protocol devi ations will be included in the monitoring plan. 1843 
 1844 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 78  OF 97 Chapter 13:  Ethics/Protection of Human Participants [ADDRESS_320174] 1846 
The investigator will ensure that this study is con ducted in full conformity with Regulations for 1847 
the Protection of Human Participants of Research co dified in 45 CFR Part 46, 21 CFR Part 50, 1848 
21 CFR Part 56, and/or the ICH E6. 1849 
13.2  Institutional Review Boards 1850 
The protocol, informed consent form(s), recruitment  materials, and all participant materials will [ADDRESS_320175] be obtained before any participant is enr olled.  Any amendment to the protocol will 1853 
require review and approval by [CONTACT_263252] c hanges are implemented to the study.  All 1854 
changes to the consent form will be IRB approved; a  determination will be made regarding 1855 
whether previously consented participants need to b e re-consented. 1856 
13.3  Informed Consent Process 1857 
13.3.1  Consent Procedures and Documentation 1858 
Informed consent is a process that is initiated pri or to the individual’s agreeing to participate in 1859 
the study and continues throughout the individual’s  study participation.  Extensive discussion of 1860 
risks and possible benefits of participation will b e provided to the participants and their families.  1861 
Consent forms will be IRB-approved, and the partici pant and if applicable, parent/guardian will [ADDRESS_320176] the 1866 
opportunity to carefully review the written consent /assent form and ask questions prior to [ADDRESS_320177] the opportunity to dis cuss the study with their surrogates or think 1869 
about it prior to agreeing to participate.  The par ticipant’s electronic consent signature [INVESTIGATOR_1317] [ADDRESS_320178] by [CONTACT_3486], their staff,  1877 
and the sponsor(s) and their agents.  This confiden tiality is extended to cover testing of [ADDRESS_320179] all documents and records 1884 
required to be maintained by [CONTACT_093], incl uding but not limited to, medical records 1885 
(office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the participants in this study.  The clinical 1886 
study site will permit access to such records. 1887 
The study participant’s contact [CONTACT_263253] 1888 
internal use during the study.  At the end of the s tudy, all records will continue to be kept in a 1889 
secure location for as long a period as dictated by  [CONTACT_3488], institutional policies, or 1890 
sponsor requirements. 1891 
Study participant research data, which is for purpo ses of statistical analysis and scientific 1892 
reporting, will be transmitted to and stored at the  Coordinating Center.  This will not include the 1893 
participant’s contact [CONTACT_1290], u nless otherwise specified in the informed [ADDRESS_320180] access to research records to refuse to 1902 
disclose identifying information on research partic ipation in any civil, criminal, administrative, 1903 
legislative, or other proceeding, whether at the fe deral, state, or local level.  By [CONTACT_263254] 1904 
researchers and institutions from being compelled t o disclose information that would identify 1905 
research participants, Certificates of Confidential ity help achieve the research objectives and 1906 
promote participation in studies by [CONTACT_4205][INVESTIGATOR_21783]. 1907 
13.3.3  Future Use of Data 1908 
Data collected for this study will be analyzed and stored at the Coordinating Center.  After the 1909 
study is completed, the de-identified, archived dat a will be archived at the Jaeb Center.  A 1910 
publicly-accessible, de-identified dataset will be made available on the Jaeb Center website 1911 
and/or the NIDDK data repository. 1912 
13.3.4  Future Use of Biologic Samples 1913 
With the participant’s approval and as approved by [CONTACT_50810], de-identified biological samples 1914 
will be shipped to the central laboratory for tempo rary storage and later batch shipped for long- 1915 
term storage at [LOCATION_005] General Hospi[INVESTIGATOR_307]. The se samples could be used for diabetes- 1916 
related research, including its treatment (includin g insulin assays), its causes, its complications [ADDRESS_320181] to biosample storage will not be possible af ter the study is completed. 1924 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 80  OF 97 Chapter 14:  Ancillary Study to Test the iLet with Inputted Bloo d 1925 
Glucose Measurements 1926 
14.1  Objective 1927 
This Ancillary Study will assess the safety of util izing blood glucose measurements instead of 1928 
CGM measurements as input into the iLet for ~48-60 hours.  The Study is intended to mirror a 1929 
real-world situation where CGM may not be available  for an extended period of time (eg, user 1930 
runs out of sensors and is awaiting new shipment).  1931 
14.2  Sample Size 1932 
Participation in the Ancillary Study will be offere d to participants who are using the iLet at the 1933 
time of the 13-week randomized trial visit. The goa l for sample size is to have234 complete the 1934 
Ancillary Study, with a goal of 71 pediatric partic ipants and 163 adults (with a goal to have 1935 
approximately half of the adults using Fiasp and ha lf using lispro/aspart).   The maximum [ADDRESS_320182] on the 1940 
day of enrollment into the Ancillary Study.   1941 
Inclusion in the Ancillary Study requires investiga tor judgment that it is safe for the individual to 1942 
participate.  1943 
Participants < [ADDRESS_320183] be living with one  or more parent/legal guardian knowledgeable 1944 
about emergency procedures for severe hypoglycemia.  Participants >[ADDRESS_320184] visit, informed conse nt (and assent where indicated) will be [ADDRESS_320185] day of the 1951 
Study will be referred to as Day 1 and the final da y as Day 3.   1952 
At the clinic visit on Day 1 (13-week visit of the RCT), participants will be trained on the study [ADDRESS_320186] to the 1955 
identification and management of hypoglycemia and h yperglycemia.  The real-time CGM sensor 1956 
will be removed and a blinded G6 Pro sensor will be  placed.   1957 
For the next ~48-[ADDRESS_320187] the blood glucose 1961 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 81  OF 97 entry every 2 hours; however, during the overnight period, only one blood glucose measurement 1962 
will be required. 1963 
Phone/video contact [CONTACT_178018] 2 for a saf ety check.  1964 
On Day 3, phone/video contact [CONTACT_263255] [ADDRESS_320188]. 1969 
14.5  Outcomes and Analysis Plan 1970 
A separate statistical analysis plan will be writte n for the Ancillary Study. 1971 
Outcomes will include the following: 1972 
Key Safety Outcomes: 1973 
• Severe hypoglycemia 1974 
• Diabetic ketoacidosis 1975 
• Other serious adverse events 1976 
• Time <54 mg/dL 1977 
• Time >300 mg/dL 1978 
• CGM-measured hypoglycemic events 1979 
• CGM-measured hyperglycemic events 1980 
Other Outcomes 1981 
• Mean glucose 1982 
• Time 70-180 mg/dL 1983 
• Time >180 mg/dL 1984 
• Time >250 mg/dL 1985 
• Standard deviation 1986 
• Time <70 mg/dL 1987 
• Coefficient of variation [ADDRESS_320189], a s described in section 9.6.  Additionally, an 1993 
initial analysis of the safety outcomes listed in s ection 14.5 will be performed after data are 1994 
available from 20 participants.     1995 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 82  OF 97  1996 
Appendix A:  Prior Studies Conducted Using the 1997 
Bionic Pancreas System 1998 
A.1  Studies Conducted with the iPhone-Based BP System 1999 
A.1.1  The Beacon Hill Study, the 2013 and 2014 Summer Cam p Studies, and the 2000 
Bionic Pancreas Multi-Center Study 2001 
All of our preclinical studies at BU testing our BP  in a diabetic swine model of T1D (between 2002 
2005 and 2009), and all of our inpatient clinical t rials in the Clinical Research Center at MGH 2003 
testing our BP in adults and adolescents with T1D ( between 2008 and 2012) set the stage for the [ADDRESS_320190] outpatient study testing our biho rmonal BP in adults 21 years or older with 2006 
T1D.  This study, which we referred to as the Beaco n Hill Study, followed a random-order 2007 
cross over design in which 20 adults with T1D parti cipated in 5 days on our iPhone-Based BP 2008 
and 5 days of usual care. In the usual-care control  arm the participants used conventional insulin 2009 
pump therapy (and their own CGM if they had one), a nd they wore a CGM with blinded display 2010 
and muted alarms.  In the BP arm, participants kept  to a three-square-mile geographic area 2011 
centered around the Beacon Hill neighborhood in Bos ton.  They ate as they chose at local 2012 
restaurants, and exercised at will with access to t wo gyms.  Analysis was pre-specified to focus 2013 
on Days 2–5, since glycemic control is more represe ntative of BP performance after most of the 2014 
adaptation by [CONTACT_179334] 1. Results are s ummarized in the plots and table of Figure 2. 2015 
 2016 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 83  OF 97  2017 
 2018 
Figure 2.  Outpatient results summarizing the distribution of  mean CGM glucose levels and 2019 
hypoglycemia in the bihormonal BP and control arms from the Beacon Hill Study, 2013 and 2020 
2014 Summer Camp Studies, and the Bionic Pancreas M ulti-Center Study.  Mean CGM glucose 2021 
levels for each participant under usual care (shown  as a red circle on the left) is connected with 2022 
the participant's mean CGM glucose level on the BP (shown as a black circle on the right). [ADDRESS_320191] diameter is propor tional to the percentage of CGM glucose values 2024 
< 60 mg/dl, and the size of the triangle is proport ional to the percentage of CGM glucose values 2025 
> 180 mg/dl.  The heavy circles and lines represent  the group means.  The horizontal red dashed 2026 
Mean CGMG (mg/dl)
90 120 154 180 210 240 1% <60 mg/dl 
5% <60 mg/dl 
10% >180 mg/dl 
50% >180 mg/dl 
Bionic 
Pancreas Control Beacon Hill S tudy 
Mean CGMG (mg/dl)
90 120 169 180 210 240 1% <60 mg/dl 
5% <60 mg/dl 
10% >180 mg/dl 
50% >180 mg/dl 
Bionic 
Pancreas Control 2013 S ummer C amp S tudy 
Mean CGMG (mg/dl)
90 120 150 169 180 210 240 1% <60 mg/dl 
5% <60 mg/dl 
10% >180 mg/dl 
50% >180 mg/dl 
Bionic 
Pancreas Control 2014 S ummer C amp S tudy 
Mean CGMG (mg/dl)
90 120 154 180 210 240 1% <60 mg/dl 
5% <60 mg/dl 
10% >180 mg/dl 
50% >180 mg/dl 
Bionic 
Pancreas Control BP Multi-C enter S tudy 
Study Age Mean CGM Mean CGM Mean CGM
(years) glucose level <"60"mg/dl 70–180"mg/dl glucose level <"60"mg/dl 70–180"mg/dl glucose level <"60"mg/dl 70–180"mg/dl
(mg/dl) (%) (%) (mg/dl) (%) (%)
Beacon Hill  (n=20, 5-day experiments) ≥* 21 133 1.5 80 159 3.7 59 <* 0.001 0.020 <* 0.001
2013 Summer Camp  (n=32, 5-day experiments) 12–20 142 1.3 76 158 2.2 65 0.004 0.192 <* 0.001
2014 Summer Camp  (n=19, 5-day experiments) 6–11 137 1.2 81 168 2.8 58 0.004 0.001 <* 0.001
BP Multi-Center  (n=39, 11-day experiments) ≥* 18 141 0.6 78 162 1.9 62 <* 0.001 <* 0.001 <* 0.001Bionic Pancreas (BP) Control p-value (BP versus Control) for:
% of CGM glucose levels % of CGM goucose values % of CGM glucose values
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 84  OF 97 line refers to the glucose level corresponding to t he ADA therapy goal for each age group tested, 2027 
which corresponds to 154 mg/dl (HbA1c < 7%) for adu lts with T1D ≥ 18 years old and 169 2028 
mg/dl (HbA1c < 7.5%) for children with T1D < 18 yea rs old.  Results are summarized in the 2029 
table below the plots, where the co-primary outcome s (mean CGM glucose level and percentage 2030 
of CGM glucose values < 60 mg/dl) for the BP are hi ghlighted in red for each of the four studies. [ADDRESS_320192] outpatient study testing our 2032 
bihormonal BP in adolescents 12–20 years old with T 1D.  This study, which we referred to 2033 
as the 2013 Summer Camp Study, followed a random-or der cross-over design in which 2034 
32 adolescents with T1D participated in 5 days on o ur BP and 5 days of supervised camp care in 2035 
the control arm.  In the control arm the participan ts used conventional insulin pump therapy (and 2036 
their own CGM if they had one), and they wore the B P without pumps and with blinded display 2037 
and muted alarms for remote monitoring.  Participan ts were monitored remotely according to 2038 
identical criteria in all study arms for proper dev ice functioning and CGM glucose < 70 mg/dl [ADDRESS_320193] udy staff to call the participant and make 2040 
sure they were treated.  Participants were fully in tegrated into normal camp activities without 2041 
restrictions on diet or exercise.  The mean HbA1c o f all 32 participants at baseline (pre-study) 2042 
was 8.2%, which corresponds to a mean BG of 189 mg/ dl.  Results are summarized in the plots [ADDRESS_320194] outpatient study testing our 2045 
bihormonal BP in pre-adolescents 6–[ADDRESS_320195] our BP in adults 18 years or older with T1D.  This study, which 2050 
we referred to as the BPMC Study, followed a random -order cross-over design in which 39 2051 
adults participated in 11 days on our BP and 11 day s of usual care.  Participants went to work as 2052 
usual, and lived and slept at home, all without cli nical supervision.  There were no restrictions 2053 
placed on diet or exercise.  The study included fou r medical centers (10 participants per center), [ADDRESS_320196] study testing the BP at different 2059 
static glucose targets (“set-points”) in both the b ihormonal and insulin-only configurations.  2060 
In this study, which we referred to as the MGH Set- point Study, 20 adults participated in 7 study 2061 
arms, each lasting 3 days.  In all of our previous studies, the target glucose for the bihormonal 2062 
BP was set to 100 mg/dl.  Since this was the first study to test the BP in a configuration without 2063 
glucagon, the insulin-only study arms initially use d significantly elevated glucose targets of 2064 
130 mg/dl and 145 mg/dl (not shown).  We subsequent ly obtained approval from the FDA to test 2065 
glucose targets of 120 mg/dl and 110 mg/dl in Decem ber 2015.  Results from the insulin-only BP [ADDRESS_320197]  with a glucose target of 120 mg/dl and the [ADDRESS_320198] w ith a glucose target of 110 mg/dl. 2072 
 2073 
Figure 3.  Outpatient results summarizing the distribution of  mean CGM glucose levels and 2074 
hypoglycemia in the insulin-only BP arms (with set- points 130, 120, and 110 mg/dl) and 2075 
usual-care arm (control) from the Bionic Pancreas S et-Point Study.  Mean CGM glucose levels 2076 
for each participant in each study arm (shown as a red circles) are connected by [CONTACT_179335].  [ADDRESS_320199] diameter is propor tional to the percentage of CGM glucose values 2078 
< 60 mg/dl.  The heavy circles and lines represent the group means.  The horizontal red dashed 2079 
line refers to the glucose level corresponding to t he ADA therapy goal for each age group tested, 2080 
which corresponds to 154 mg/dl (HbA1c <7%) for adul ts with T1D ≥ 18 years old. 2081 
M ean C G M G  (m g /d l)
90 120 154 180 210 240 1% <60 mg/dl 
5% <60 mg/dl 
C o ntro l M ean: 158 +/- 31 m g/dl 
1.4%  < 60,     34%  >180 
In su lin  O n ly 
(130 m g /d l) M ean: 161 +/- 17 m g/dl 
0.8%  < 60,     30%  >180 
I: 0.57 U /kg 
In su lin  O n ly 
(120 m g /d l) M ean: 156 +/- 15 m g/dl 
1.1%  <60,     28%  >180 
I: 0.57 U /kg 
In su lin  O n ly 
(110 m g /d l) M ean: 153 +/- 15 m g/dl 
1.3%  <60,     26%  >180 
I: 0.70 U /kg (n =20) 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 86  OF 97  2082 
Figure 4.  Outpatient results summarizing the distribution of  mean CGM glucose levels and 2083 
hypoglycemia in the bihormonal BP arms (with set-po ints of 130, 110, and 100 mg/dl) and 2084 
usual-care arm (control) from the Bionic Pancreas S et-Point Study. Mean CGM glucose levels 2085 
for each participant in each study arm (shown as a red circles) are connected by [CONTACT_179335].  [ADDRESS_320200] diameter is propor tional to the percentage of CGM glucose values 2087 
< 60 mg/dl.  The heavy circles and lines represent the group means.  The horizontal red dashed 2088 
line refers to the glucose level corresponding to t he ADA therapy goal for each age group tested, 2089 
which corresponds to 154 mg/dl (HbA1c <7%) for adul ts with T1D ≥ [ADDRESS_320201] Insulin-Only 2094 
Study, 16 adults participated in a week of usual ca re followed by [CONTACT_263256] 2095 
insulinonly BP.  Participants were monitored remote ly according to identical criteria in both 2096 
study arms for proper device functioning and CGM gl ucose <50 mg/dl lasting more than [ADDRESS_320202] week was a control arm in which  participants managed their own conventional 2099 
insulin pump therapy (using their own CGM if they h ad one) and wore the BP without pumps 2100 
and with blinded display and muted alarms for remot e monitoring.  In the second week, the BP 2101 
was initiated with target glucose of 130 mg/dl, whi ch could be lowered to 115 mg/dl if certain 2102 
criteria were met.  Results of the study are summar ized in Figure 5.  All but one participant was 2103 
kept at a target of 130 mg/dl, and one was lowered to 115 mg/dl, for an overall average target of 2104 
129 mg/dl.  During this week the mean CGM glucose o btained during the insulin-only BP arm 2105 
was 159 ± 8 mg/dl (which was similar to the mean CG M glucose of 161 ± 17 mg/dl obtained 2106 
during the insulin-only BP arm of the Bionic Pancre as Set-Point Study when the glucose target 2107 
M ean C G M G  (m g /d l)
90 120 154 180 210 240 1% <60 mg/dl 
5% <60 mg/dl 
C o ntro l M ean: 158 +/- 31 m g/dl 
1.4%  < 60,     34%  >180 
B ih o rm o n al 
(130 m g /d l) M ean: 156 +/- 12 m g/dl 
0.5%  < 60,     28%  >180 
I: 0.53 U /kg,  G : 2 .2 m cg /kg 
B ih o rm on al 
(110 m g /d l) M ean: 148 +/- 17 m g/dl 
0.4%  <60,     22%  >180 
I: 0.67 U /kg,  G : 5 .1 m cg /kg 
B ih o rm on al 
(100 m g /d l) M ean: 136 +/- 14 m g/dl 
0.8%  <60,     17%  >180 
I: 0.58 U /kg,  G : 8 .3 m cg /kg (n =20) 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 87  OF 97 was set to 130 mg/dl).  Although the mean glucose w as statistically significantly higher 2108 
(p=0.001) during the insulin-only BP arm than durin g the usual-care arm (145 ± 20 mg/dl) in the [ADDRESS_320203] Insulin -Only Study, there was a significant decrease 2110 
in the time spent <60 mg/dL during the insulin-only  BP arm relative to the usual-care arm 2111 
(mean of 0.84 ± 0.91 versus mean 2.3 ± 2.1%, p = 0. 04). [ADDRESS_320204] Insulin-Only Study.  2115 
Mean CGM glucose levels for each participant under usual care (shown as a red circle on the 2116 
left) is connected with the participant's mean CGM glucose level on the BP (shown as a black [ADDRESS_320205] on the right).  For each participant, the ci rcle diameter is proportional to the percentage of 2118 
CGM glucose values < 60 mg/dl.  The heavy circles a nd lines represent the group means.  2119 
The horizontal red dashed line refers to the glucos e level corresponding to the ADA therapy goal 2120 
for each age group tested, which corresponds to 154  mg/dl (HbA1c <7%) for adults with T1D ≥ [ADDRESS_320206]’s own usual care. [ADDRESS_320207] glucose target previously tested: 1 00 mg/dl for the bihormonal BP and 110 mg/dl 2129 
for the insulin-only BP.  The results are summarize d in Figure 6.  There was more hypoglycemia 2130 
without monitoring relative to with monitoring in t he two usual-care arms (1.95 versus 1.32%, 2131 
p=0.02).  However, there was no difference in hypog lycemia without monitoring relative to with 2132 
Mean CGMG (mg/dl)
90 120 154 180 210 240 1% <60 mg/dl 
5% <60 mg/dl 
Control Insulin Only (n=16) 
Mean: 151 +/- 26 mg/dl 
1.9% <60,     26% >180 Mean: 160 +/-  9 mg/dl 
0.9% <60,     30% >180 
I: 0.57 U/kg 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 88  OF 97 monitoring in the two bihormonal BP arms (0.99 vers us 1.05%, p=0.82) and two insulin-only BP 2133 
arms (1.66 versus 1.55%, p=0.74) arms.  Without mon itoring, hypoglycemia was reduced in the 2134 
bihormonal BP arm relative to the usual-care arm (0 .99 versus 1.95%, p=0.02) and was 2135 
comparable on the insulin-only BP relative to usual  care (1.66 versus 1.95%, p=0.47).  The mean [ADDRESS_320208] aggressive glucose set 2140 
points.  As a result of this study and the Bionic P ancreas Set-Point Study, we concluded that the 2141 
default glucose set points should be set in future studies to 110 mg/dl for the bihormonal 2142 
configuration and 120 mg/dl for insulin-only config uration.  We further concluded that users 2143 
could be allowed to lower each set point (to a mini mum of 100 mg/dl for the bihormonal 2144 
configuration and 110 mg/dl for insulin-only config uration) should they so desire without 2145 
sacrificing their safety. 2146 
 2147 
Figure 6.  Outpatient results summarizing the distribution of  mean CGM glucose levels and 2148 
hypoglycemia in the insulin-only BP and control arm s from the Bionic Pancreas Monitoring 2149 
Study.  Mean CGM glucose levels for each participan t under usual care (shown as a red circle on 2150 
the left) is connected with the participant's mean CGM glucose level on the BP (shown as a black [ADDRESS_320209] on the right).  For each participant, the ci rcle diameter is proportional to the percentage of 2152 
CGM glucose values < 60 mg/dl.  The heavy circles a nd lines represent the group means.  2153 
The horizontal red dashed line refers to the glucos e level corresponding to the ADA therapy goal 2154 
for each age group tested, which corresponds to 154  mg/dl (HbA1c <7%) for adults with T1D ≥ 2155 
18 years old. 2156 
M ean  C G M G  (m g/d l)
90 120 154 180 210 240 1% <60 mg/dl 
5% <60 mg/dl 
C o n tro l, N M ean: 165 +/- 29 m g/dl 
2.0%  <60,     36%  >180 
C o n tro l, Y M ean: 164 +/- 29 m g/dl 
1.3%  <60,     36%  >180 
In su lin  O n ly 
110 m g /d l, N M ean: 148 +/- 11 m g/dl 
1.7%  <60,     24%  >180 
I: 0 .5 9 U /kg 
In su lin  O n ly 
110 m g /d l, Y M ean: 151 +/- 13 m g/dl 
1.6%  <60,     26%  >180 
I: 0 .6 1 U /kg 
B ih o rm o n al 
100 m g /d l, N M ean: 139 +/- 11 m g/dl 
1.0%  <60,     19%  >180 
I: 0 .6 4 U /kg ,  G : 7.4 m cg /k g 
B ih o rm o n al 
100 m g /d l, Y M ean: 139 +/- 13 m g/dl 
1.0%  <60,     18%  >180 
I: 0 .6 2 U /kg ,  G : 7.1 m cg /k g (n =23) 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE [ADDRESS_320210] University in adult subjec ts ≥ [ADDRESS_320211]’s own usual ca re (UC) for 7 days each.  The study enrolled 2167 
12 subjects who used multiple daily injection thera py and 22 subjects who used insulin-pump 2168 
therapy for their UC. Participants enrolled at MGH (n = 17) used the Senseonics Eversense CGM [ADDRESS_320212] (n = 17) used the G5 Dexcom  CGM as the input CGM signal for the iLet.  [ADDRESS_320213] is shown over Days 3–7 under 2174 
usual care, (left panel), on the iLet in the insuli n-only configuration using lispro or aspart 2175 
(middle panel), and on the iLet in the insulin-only  configuration using Fiasp (right panel).  [ADDRESS_320214] is proportional to the percentage time spent < 60 mg/dl for each [ADDRESS_320215] under each study arm over Days 3–7.  The me an CGM glucose was 155 ± 13 mg/dl with 2178 
the iLet in the insulin-only configuration using li spro or aspart, 155 ± 11 mg/dl with the iLet in 2179 
the insulin-only configuration using Fiasp, and 163  ± 26 mg/dl under usual care.  The time < 60 2180 
mg/dl was 1.2% using lispro or aspart, 1.2% with th e iLet using Fiasp, and 1.3% under usual 2181 
M ean  C G M G  (m g /d l)
90 120 154 180 210 240 1% <60 mg/dl 
5% <60 mg/dl (n =35) 
C o n tro l (33%  A D A ) M ean: 163 + /- 26 m g/dl 
1.30%  <60,     35%  >180 
In su lin  O n ly (42%  A D A ) M ean: 155 +/- 13 m g/dl 
1.19%  <60,     27%  >180 
I: 0.6 5 U /kg 
In su lin  O n ly (44%  A D A ) 
(F iasp ) M ean: 155 +/- 11 m g/dl 
1.19%  <60,     27%  >180 
I: 0 .6 4 U /kg 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE [ADDRESS_320216] (1) two different CGM devices, (2) an 2186 
ultra-rapid insulin analog, and (3) a cohort that w as comprised subjects coming from multiple 2187 
daily injection (MDI) therapy and insulin pump ther apy.  Since only the patient’s body weight is 2188 
required to initialize the iLet, and no other infor mation is required about either insulin therapy 2189 
regimen (either MDI or insulin pump therapy), the i Let is the only device that can be tested in [ADDRESS_320217] require transition to pump therapy 2191 
and weeks-long run-in periods or device training pe riods to determine a baseline pump therapy 2192 
regimen before automated insulin delivery can be in itiated.  The iLet, on the other hand, requires 2193 
no run-in periods or device training periods; it is  ideally suited, therefore, for use in underserved 2194 
populations, in insulin-pump-naïve populations, and  in populations where endocrinologists and 2195 
diabetologists are not available or in short supply .  The Insulin-Only Bionic Pancreas Bridging 2196 
Study demonstrated that the iLet performed equally well on subjects coming from MDI therapy 2197 
as it did on subjects coming from insulin pump ther apy (see Figure 7). [ADDRESS_320218] 2018 at Nemours Children’s [ADDRESS_320219] University 2201 
in pediatric subjects 6–17 years old with type 1 di abetes.  The study was designed as a 2202 
random-order, cross-over, outpatient trial that com pared the insulin-only configuration of the 2203 
iLet (using lispro or aspart) to each subject’s own  usual care (UC) for 5 days each.  The study 2204 
enrolled 20 subjects who used insulin-pump therapy for their UC (n = 6 at Nemours, n = 6 at 2205 
Colorado, and n = [ADDRESS_320220]).  Results from the  Pediatric Transitional Study are summarized [ADDRESS_320221] is shown over Days 2–[ADDRESS_320222] is 2213 
proportional to the percentage time spent < 60 mg/d l for each subject under each study arm over 2214 
Days 2–5.  The mean CGM glucose with the iLet in th e insulin-only configuration was 162 ± 16 2215 
mg/dl and the CGM glucose was < 60 mg/dl 0.8% of th e time, whereas the mean CGM glucose 2216 
under usual care was 161± 28 mg/dl and the CGM gluc ose was < 60 mg/dl 1.0% of the time. 2217 
 2218 
A.2.3  The iLet Bihormonal Cross-Over Study 2219 
The Bihormonal Cross-Over Study was conducted in Ma y and June 2019 at MGH in adult 2220 
subjects ≥ 18 years old with type 1 diabetes.  The study was designed as a random-order, cross- 2221 
over, home-use trial that compared the insulin-only  configuration of the iLet using lispro or 2222 
aspart to the bihormonal configuration of the iLet using lispro or aspart and dasiglucagon (4 2223 
mg/ml) for 7 days each.  The study enrolled 10 subj ects who used insulin-pump therapy for their 2224 
usual care.  Results from the Bihormonal Cross-Over  Study are summarized in Figure 9. 2225 
 2226 
M ean C G M G  (m g/dl)
90 120 169 180 210 240 1% <%60 mg/dl 
5% <%60 mg/dl 
C ontrol (55%  A D A ) M ean: 161 +/- 28 m g/dl 
1.0%  <% 60,     33%  > 180 
Insulin O nly (75%  A D A ) M ean: 162 + /- 16 m g/dl 
0.8%  < % 60,     32%  >180 
I: 0.94 U /kg (n=20) 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE [ADDRESS_320223] is shown ov er Days 2–[ADDRESS_320224] 2231 
is proportional to the percentage time spent < 54 m g/dl for each subject under each study arm 2232 
over Days 2–7.  The mean CGM glucose with the iLet in the insulin-only configuration was 149 2233 
± 13 mg/dl and the CGM glucose was < 54 mg/dl 0.6% of the time, whereas the mean CGM 2234 
glucose with the iLet in the bihormonal configurati on with dasiglucagon was 139 ± 11 mg/dl and 2235 
the CGM glucose was < 54 mg/dl 0.3% of the time. 2236 
iPhone bionic pancreas (BP) and iLet BP Studies – I nsulin-only exposure only 2237 
 2238 
 Year Name [CONTACT_263258],  
Population,  
Device 
exposure 1 BP 
Configuratio 
n,  
Set Points 
tested, 
Medications 
used  Protocol 
Description Results:  
Mean CGM 
glucose, % < 60 Conclusion 
s 
1 201 
5-
201 
6 BP Set 
Point 
Study 
 
IDE: 
G150130 Outpatient, 
unsupervised 
at home 
 
20 adults aged 
18 and older 
 
4 arms, 4 days 
each  Insulin-only 
iPhone BP 
with one 
Tandem 
t:slim pump 
and Dexcom 
G4 AP CGM 
 
Glucose RCT with [ADDRESS_320225] testing of 110 mg/dl: 
153±15 mg/dl, 
1.3% 
 
120 mg/dl:  
156±15 mg/dl, 
1.1% 
 
130 m g/dl:  The results 
of this 
study 
helped 
identify the 
glucose 
target 
settings 
that will be 

 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 93  OF 97  
7,680 hours targets:  
110 mg/dl 
120 mg/dl 
130 mg/dl  
145 mg/dl 
 
Insulin lispro 
(Eli Lilly) & 
Insulin aspart 
(Novo 
Nordisk) 
 the insulin-
only 
algorithm.  
 
 
Remote 
telemetric 
monitoring 
 
 161±17 mg/dl, 
0.8% 
 
145 mg/dl:  
174±23 mg/dl, 
1.0% 
 
UC:  
158±31 mg/dl, 
1.4% used in 
future 
studies. 
These were 
set to range 
from 110 
mg/dl to 
130 mg/dl, 
with a 
default of 
120 mg/dl. 
[ADDRESS_320226] 
Insulin-
only 
Study 
 
IDE: 
G150142 Outpatient, 
unsupervised 
at home 
 
16 adults aged 
18 and older 
 
2 arms, 7 days 
each 
 
5,376 hours Insulin-only 
iPhone BP 
with one 
Tandem 
t:slim pump 
and Dexcom 
G4 AP CGM 
 
Glucose 
targets:  
115 to 130 
mg/dl 
 
Insulin lispro 
(Eli Lilly) & 
Insulin aspart 
(Novo 
Nordisk)  RCT 
comparing 
insulin-only 
BP with usual 
care 
 
Remote 
telemetric 
monitoring 
 
 BP:  
160±9 mg/dl, 
0.9%  
 
UC:  
151±26 mg/dl, 
1.9% The results 
of this 
study 
helped 
identify the 
glucose 
target 
settings 
that will be 
used in 
future 
studies. 
3 201 
7 Monitori 
ng Study 
 
IDE: 
G150130 Outpatient, 
unsupervised 
at home 
 
23 adults aged 
18 and older 
 
2 arms, 7 days 
each 
 
7,728 hours Insulin-only 
iPhone BP 
with one 
Tandem 
t:slim pump 
and Dexcom 
G5 CGM 
 
Glucose 
target:  
110 mg/dl 
 
Insulin lispro 
(Eli Lilly) & 
Insulin aspart 
(Novo 
Nordisk) 
 RCT with the 
insulin-only 
BP set at the 
lowest 
allowed 
glucose target 
for the insulin-
only system, 
repeated with 
and without 
monitoring for 
hypoglycemia, 
and compared 
with usual 
care and the 
bihormonal 
BP. 
 
Remote 
telemetric 
monitoring in With monitoring: 
Insulin-only: 
151±13 mg/dl, 
1.6% 
 
UC:  
164±29 mg/dl, 
1.3% 
 
Without 
monitoring: 
Insulin-only: 
148±11 mg/dl, 
1.7% 
 
UC: 
165±29 mg/dl, 
2.0% The results 
of this 
study 
confirmed 
that the 
insulin-
only BP set 
at the 
lowest 
possible 
glucose 
target (110 
mg/dl) was 
safe to be 
used in the 
outpatient 
setting 
without 
any remote 
monitoring 
for 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 94  OF 97 half of the 
study arms.  hypoglyce 
mia.  
 
4 2018 Adult 
Bridging 
study 
 
IDE: 
G180083 Outpatient, 
unsupervised 
at home, 2 
centers 
 
34 adults aged 
18 and older 
 
2 arms, 7 days 
each 
 
11,424 hours Insulin-only 
Gen 3 iLet 
BP using 
Senseonics 
Eversense 
CGM (MGH) 
or Dexcom 
G5 CGM 
(Stanford) 
 
Glucose 
target:  
120 mg/dl 
 
Insulin lispro 
(Eli Lilly),  
Insulin aspart 
(Novo 
Nordisk) & 
Fiasp 
PumpCart 
(Novo 
Nordisk) RCT 
comparing the 
insulin-only 
BP in 2 arms 
with usual 
care.  
 
One BP arm 
used insulin 
lispro or 
aspart, the 
other BP arm 
used Fiasp. 
The BP was 
set at the 
default 
glucose target 
of 120 and 
tmax setting 
of 65 minutes 
for both arms.  
 
Remote 
telemetric 
monitoring BP: 
155±13 mg/dl, 
1.19% 
 
BP with Fiasp:  
155±11 mg/dl, 
1.19% 
 
UC: 
163±26 mg/dl, 
1.30% The results 
of this 
study 
demonstrat 
ed that the 
insulin-
only iLet 
BP was 
safe and 
effective 
using both 
Fiasp or 
aspart/lispr 
o at the 
default PK 
settings 
consistent 
with the 
results of 
the iPhone 
BP studies, 
preparing 
the path for 
a larger and 
longer 
study using 
the same 
device 
settings 
and 
insulins.  
5 2018 Day-
camp 
Transitio 
nal Study 
 
IDE: 
G180083 Supervised 
day camp 
setting 
followed by 
[CONTACT_263257], 2 
centers 
 
20 children 
aged 6-17 
 
5 days 
 
2,400 hours Insulin-only 
Gen 3 iLet 
BP using 
Dexcom G5 
CGM 
 
Glucose 
target:  
120 mg/dl 
 
Insulin lispro 
(Eli Lilly) & 
Insulin aspart 
(Novo 
Nordisk) RCT 
comparing the 
insulin-only 
BP with usual 
care.  
 
Remote 
telemetric 
monitoring BP: 
162±16 mg/dl, 
0.8% 
 
UC: 
161±28 mg/dl, 
1.0% The results 
of this 
study 
demonstrat 
ed that 
under 
stressful 
conditions, 
the insulin-
only iLet 
BP was 
safe and 
effective to 
use in 
adolescent 
and pre-
adolescent 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 95  OF 97 children, 
preparing 
the path for 
a larger and 
longer 
study using 
the same 
device 
settings in 
this age 
group.  
6 2019 Fiasp 
Explorat 
ory Study 
 
IDE: 
G180150 48 hour 
supervised 
hotel stay, 
followed by 5 
days 
unsupervised 
at home 
 
24 adults aged 
18 and older 
 
2 arms, 7 days 
each 
 
8,064 hours Insulin-only 
Gen 3 iLet 
BP using 
Dexcom G5 
CGM 
 
Glucose 
target:  
120 mg/dl 
 
Fiasp 
PumpCart 
(Novo 
Nordisk) RCT to 
compare 
default insulin 
PK settings 
(tmax = 65 
minutes) with 
faster PK 
settings (tmax 
= 50, 40 and 
30 minutes). 
Faster PK 
setting was 
escalated over 
three cohorts 
of 8 subjects 
 
Remote 
telemetric 
monitoring  Pending analysis.  
7 2019 Bihormo 
nal 
Crossove 
r Study 
 
IDE: 
G190028 Outpatient, 
unsupervised 
at home 
 
10 adults aged 
18 and older 
 
7 days 
 
1,680 hours Insulin-only 
Gen 3 iLet 
BP using 
Dexcom G5 
CGM 
 
Glucose 
target:  
120 mg/dl 
 
Insulin lispro 
(Eli Lilly) & 
Insulin aspart 
(Novo 
Nordisk) RCT to 
compare 
insulin-only 
with 
bihormonal 
using 
dasiglucagon, 
testing 
bihormonal 
iLet for the 
first time 
 
Remote 
telemetric 
monitoring Insulin-only: 
149±13 mg/dl, 
1.25% The results 
of this 
study 
confirm the 
insulin-
only iLet 
BP at the 
lowest 
target 
glucose set 
point is 
safe and 
effective in 
the 
outpatient 
setting, 
consistent 
with results 
achieved in 
the iphone 
BP studies.  
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 96  OF 97 8 2019 MultiPK 
BP Study 
 
IDE: 
G180254 Outpatient, 
unsupervised 
at home 
 
6 adults aged 
18 and older 
completed to 
date 
 
3 arms, 7 days 
each 
 
3,024 hours Insulin-only 
Gen 3 iLet 
BP using 
Dexcom G5 
CGM 
 
Glucose 
target:  
120 mg/dl 
 
Insulin lispro 
(Eli Lilly),  
Insulin aspart 
(Novo 
Nordisk) & 
BioChaperon 
e lispro 
(Adocia)  RCT with one 
week each on 
insulin lispro, 
insulin aspart 
and 
BioChaperone 
lispro using 
the default 
tmax setting 
(65 minutes) 
for all three 
insulins 
 
Remote 
telemetric 
monitoring Pending analysis, experiments 
ongoing 
1 – Total device exposure is calculated based on co hort size used in the study analysis and includes 2239 
insulin-only arms only 2240 
  2241 
 
IOBP_PI[INVESTIGATOR_263198]_PROTOCOL_V10.0_25APR2021_C LEAN  P AGE 97  OF 97 Pediatric iPhone bionic pancreas (BP) and iLet BP s tudies – insulin-only and bihormonal (ages 6 to < 1 8 2242 
years) 2243 
 Yea 
r Name 
[CONTACT_263258],  
Population,  
Device 
exposure 1 BP 
Configura-
tion,  
Set Points 
tested, 
Medication 
s used  Protocol 
Description Results:  
Mean CGM 
glucose, % < 
60 Conclusio 
ns 
1 201 
3 2013 
Summer 
Camp 
Study 
 
IDE: 
G13006 
5 Supervised 
summer 
camp setting 
 
32 
adolescents 
aged 12 to 
20 
 
5 days 
 
3,840 hours Bihormonal 
iPhone BP 
with two 
Tandem 
t:slim 
pumps and 
Dexcom G4 
AP CGM 
 
Glucose 
target:  
100 mg/dl 
 
Insulin 
lispro (Eli 
Lilly) & 
Glucagon 
(Eli Lilly)  RCT 
comparing 
bihormonal 
iPhone BP 
with usual 
care at camp 
 
Remote 
telemetric 
monitoring BP:  
142±12 mg/dl, 
1.3%  
 
UC: 
158±27 mg/dl, 
2.2% The 
results of 
this study 
demonstr 
ated that 
under 
stressful 
condition 
s, the 
bihormon 
al BP was 
safe and 
effective 
to use in 
adolescen 
t 
children. 
2 201 
4 2014 
Summer 
Camp 
Study 
 
IDE: 
G13006 
5 Supervised 
summer 
camp setting 
 
19 pre-
adolescents 
aged 6 to 11 
 
5 days 
 
2,280 hours Bihormonal 
iPhone BP 
with two 
Tandem 
t:slim 
pumps and 
Dexcom G4 
AP CGM 
 
Glucose 
target:  
100 mg/dl 
 
Insulin 
lispro (Eli 
Lilly) & 
Glucagon 
(Eli Lilly)  RCT 
comparing 
bihormonal 
iPhone BP 
with usual 
care at camp 
 
Remote 
telemetric 
monitoring BP: 
137±11 mg/dl, 
1.2% 
 
UC: 
168±30 mg/dl, 
2.8% The 
results of 
this study 
demonstr 
ated that 
under 
stressful 
condition 
s, the 
bihormon 
al BP was 
safe and 
effective 
to use in 
pre-
adolescen 
t children 
        
 2244 